AB 1060: Health care coverage: naloxone hydrochloride.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2023-09-18
Current Status:
Failed
(2024-01-30: Consideration of Governor's veto stricken from file.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law sets forth various programs relating to opioid overdose prevention and treatment, including, among others, standing orders for the distribution of an opioid antagonist, a naloxone grant program, and a grant program to reduce fentanyl overdoses and use throughout the state.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Under existing law, the pharmacist service of furnishing naloxone hydrochloride is a covered Medi-Cal benefit. The Medi-Cal program also covers certain medications to treat opioid use disorders as part of narcotic treatment program services, or as part of medication-assisted treatment services within the Drug Medi-Cal Treatment Program, as specified.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would make legislative findings relating to the United States Food and Drug Administration (FDA) approving a certain naloxone hydrochloride nasal spray for nonprescription use.
Under the bill, prescription or nonprescription naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose would be a covered benefit under the Medi-Cal program. The bill would require a health care service plan contract or health insurance policy that provides coverage for prescription drugs and that is issued, amended, delivered, or renewed on or after January 1, 2025, to cover prescription and nonprescription naloxone hydrochloride and all other drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose. The bill would prohibit a health care service plan contract or health insurance policy that provides coverage for prescription drugs from imposing any cost-sharing requirements for that coverage exceeding $10 per package of medication, as specified, would require point-of-sale coverage for over-the-counter, FDA-approved naloxone hydrochloride or another FDA-approved drug or product for the complete or partial reversal of an opioid overdose at in-network pharmacies, and would prohibit a high deductible health plan from imposing cost sharing, as specified. The bill would repeal these provisions on January 1, 2030.
Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law sets forth various programs relating to opioid overdose prevention and treatment, including, among others, standing orders for the distribution of an opioid antagonist, a naloxone grant program, and a grant program to reduce fentanyl overdoses and use throughout the state.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Under existing law, the pharmacist service of furnishing naloxone hydrochloride is a covered Medi-Cal benefit. The Medi-Cal program also covers certain medications to treat opioid use disorders as part of narcotic treatment program services, or as part of medication-assisted treatment services within the Drug Medi-Cal Treatment Program, as specified.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would make legislative findings relating to the United States Food and Drug Administration (FDA) approving a certain naloxone hydrochloride nasal spray for nonprescription use.
Under the bill, prescription or nonprescription naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose would be a covered benefit under the Medi-Cal program. The bill would require a health care service plan contract or health insurance policy that provides coverage for prescription drugs and that is issued, amended, delivered, or renewed on or after January 1, 2025, to cover at least one product of each available dosage form of the same medications under the same conditions. prescription and nonprescription naloxone hydrochloride and all other drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose. The bill would prohibit a health care service plan contract or health insurance policy that provides coverage for prescription drugs from imposing any cost-sharing requirements for that coverage exceeding $10 per package of medication, as specified, would require point-of-sale coverage for over-the-counter, FDA-approved naloxone hydrochloride at in-network pharmacies, and would prohibit a high deductible health plan from imposing cost sharing, as specified. The bill would repeal these provisions on January 1, 2030.
Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law sets forth various programs relating to opioid overdose prevention and treatment, including, among others, standing orders for the distribution of an opioid antagonist, a naloxone grant program, and a grant program to reduce fentanyl overdoses and use throughout the state.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Under existing law, the pharmacist service of furnishing naloxone hydrochloride is a covered Medi-Cal benefit. The Medi-Cal program also covers certain medications to treat opioid use disorders as part of narcotic treatment program services, or as part of medication-assisted treatment services within the Drug Medi-Cal Treatment Program, as specified.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would make legislative findings relating to the United States Food and Drug Administration (FDA) approving a certain naloxone hydrochloride nasal spray for nonprescription use.
Under the bill, prescription or nonprescription naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose would be a covered benefit under the Medi-Cal program. The bill would require a health care service plan contract or health insurance policy, as specified, to include coverage for policy issued, amended, delivered, or renewed on or after January 1, 2025, to cover at least one product of each available dosage form of the same medications under the same conditions. The bill would prohibit a health care service plan contract or health insurance policy from imposing any cost-sharing requirements for that coverage exceeding $10 per package of medication, as specified, would require point-of-sale coverage for over-the-counter, FDA-approved naloxone hydrochloride at in-network pharmacies, and would prohibit a high deductible health plan from imposing cost sharing, as specified. The bill would repeal these provisions on January 1, 2030.
Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law sets forth various programs relating to opioid overdose prevention and treatment, including, among others, standing orders for the distribution of an opioid antagonist, a naloxone grant program, and a grant program to reduce fentanyl overdoses and use throughout the state.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Under existing law, the pharmacist service of furnishing naloxone hydrochloride is a covered Medi-Cal benefit. The Medi-Cal program also covers certain medications to treat opioid use disorders as part of narcotic treatment program services, or as part of medication-assisted treatment services within the Drug Medi-Cal Treatment Program, as specified.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would make legislative findings relating to developments within the United States Food and Drug Administration (FDA) on potentially approving a certain naloxone hydrochloride nasal spray for nonprescription use.
Under the bill, prescription or nonprescription naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose would be a covered benefit under the Medi-Cal program, if that medication is approved, for prescription or nonprescription use, respectively, by the FDA for treatment of an opioid overdose. program. The bill would require a health care service plan contract or health insurance policy, as specified, to include coverage for that same medication the same medications under the same conditions. The bill would prohibit a health care service plan contract or health insurance policy from imposing any cost-sharing requirements for that coverage, would prohibit the department from subjecting that coverage to any share-of-cost requirements under the Medi-Cal program, and would require that coverage to include the total cost of that medication. coverage exceeding $10 per package of medication, and would prohibit a high deductible health plan from imposing cost sharing, as specified. The bill would repeal these provisions on January 1, 2030.
Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law sets forth various programs relating to opioid overdose prevention and treatment, including, among others, standing orders for the distribution of an opioid antagonist, a naloxone grant program, and a grant program to reduce fentanyl overdoses and use throughout the state.
Existing law establishes the Medi-Cal program, which is administered by the State Department of Health Care Services and under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Under existing law, the pharmacist service of furnishing naloxone hydrochloride is a covered Medi-Cal benefit. The Medi-Cal program also covers certain medications to treat opioid use disorders as part of narcotic treatment program services, or as part of medication-assisted treatment services within the Drug Medi-Cal Treatment Program, as specified.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would make legislative findings relating to developments within the United States Food and Drug Administration (FDA) on potentially approving a certain naloxone hydrochloride nasal spray for nonprescription use.
Under the bill, prescription or nonprescription naloxone hydrochloride would be a covered benefit under the Medi-Cal program, if that medication is approved, for prescription or nonprescription use, respectively, by the FDA for treatment of an opioid overdose. The bill would require a health care service plan contract or health insurance policy, as specified, to include coverage for that same medication under the same conditions. The bill would prohibit a health care service plan contract or health insurance policy from imposing any cost-sharing requirements for that coverage, would prohibit the department from subjecting that coverage to any share-of-cost requirements under the Medi-Cal program, and would require that coverage to include the total cost of that medication.
Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Emergency Medical Services System and the Prehospital Emergency Medical Care Personnel Act, establishes the Emergency Medical Services Authority. Under existing law, the authority is responsible for the coordination and integration of all state activities concerning emergency medical services.This bill would make technical, nonsubstantive changes to those provisions.Existing law, the Emergency Medical Services System and the Prehospital Emergency Medical Care Personnel Act, establishes the Emergency Medical Services Authority. Under existing law, the authority is responsible for the coordination and integration of all state activities concerning emergency medical services.
This bill would make technical, nonsubstantive changes to those provisions.
The Legislature finds and declares all of the following:
(a)According to the United States Food and Drug Administration (FDA), naloxone hydrochloride is a medicine that can counter overdose effects when administered timely and that can help to reduce opioid overdose deaths.
(b)In November 2022, the FDA issued a Federal Register notice with a preliminary assessment of the safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use, in order to facilitate the development and approval of those products, including through a potential switch from prescription status to nonprescription status.
(c)In February 2023, an advisory committee to the FDA voted unanimously in favor of making Narcan, a naloxone hydrochloride nasal spray, available over the counter.
(d)In March 2023, the FDA approved Narcan for nonprescription use.
(e)The California Overdose Surveillance Dashboard, administered by the State Department of Public Health, contains the following data applicable to the state for 2021:
(1)Seven thousand one hundred seventy-five deaths were documented as relating to an opioid overdose. Of those deaths, 5,961 were documented as relating to a fentanyl overdose.
(2)Eight hundred forty-six deaths were associated with an opioid-related overdose for persons 24 years of age or younger. Of those deaths, 801 were associated with a fentanyl-related overdose.
(3)Twenty-one thousand sixteen emergency department (ED) visits were documented as relating to an opioid overdose. Of those ED visits, 5,644 were associated with a fentanyl-related overdose.
SEC. 2.Section 1374.198 is added to the Health and Safety Code, immediately following Section 1374.197, to read:1374.198.(a)A health care service plan contract that provides coverage for prescription drugs and that is issued, amended, delivered, or renewed on or after January 1, 2025, shall cover prescription and nonprescription naloxone hydrochloride and all other drugs or products approved by the United States Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose.
(b)A health care service plan contract that provides coverage for prescription drugs shall not impose any cost-sharing requirements, including a copayment, coinsurance, or deductible, for coverage provided pursuant to this section exceeding ten dollars ($10) per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
(c)(1)If a health care service plan maintains a drug formulary grouped into tiers, the copayment of not more than ten dollars ($10) pursuant to subdivision (b) shall apply only to naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose that is in Tier 1 or Tier 2 or that is provided over-the-counter at an in-network pharmacy.
(2)A health care service plan that maintains a drug formulary grouped into tiers shall include, for each of the plans formularies, in Tiers 1 and 2 combined, at least two drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
(d)(1)Point-of-sale coverage for over-the-counter, FDA-approved naloxone hydrochloride or another drug or product approved by the FDA for over-the-counter complete or partial reversal of an opioid overdose shall be provided at in-network pharmacies.
(2)A health care service plan contract may impose a limit on the quantity of over-the-counter, FDA-approved naloxone hydrochloride covered if a reasonable limit is established by the department in coordination with the Department of Insurance.
(3)For purposes of this section, point-of-sale means the ability to charge only the applicable cost sharing amount for an over-the-counter, FDA-approved opioid reversal or partial reversal drug or product at the time of purchase.
(e)If a health care service plan contract is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose cost sharing as specified in this section, unless not applying cost sharing would conflict with federal requirements for high deductible health plans.
(f)This section does not limit the provisions of Sections 1342.7, 1342.73, 1367.206, 1367.24, 1367.241, and 1367.244 with respect to prescription naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose.
(g)Coverage provided pursuant to this section shall be provided consistent with guidance issued by the FDA in connection with drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
(h)A health care service plan contract that provides coverage for prescription drugs pursuant to this section may require an enrollee to obtain naloxone hydrochloride or another drug or product approved by the FDA for the complete or partial reversal of an opioid overdose from a network provider, consistent with this chapter.
(i)This section does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14590) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.
(j)The director may issue guidance to health care service plans regarding compliance with this section. This guidance shall not be subject to the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The department shall consult with the Department of Insurance in issuing the guidance specified in this subdivision.
(k)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 3.Section 10127.22 is added to the Insurance Code, immediately following Section 10127.20, to read:10127.22.(a)A health insurance policy that provides coverage for prescription drugs and that is issued, amended, delivered, or renewed on or after January 1, 2025, shall cover prescription and nonprescription naloxone hydrochloride and all other drugs or products approved by the United States Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose.
(b)A health insurance policy that provides coverage for prescription drugs shall not impose any cost-sharing requirements, including a copayment, coinsurance, or deductible, for coverage provided pursuant to this section exceeding ten dollars ($10) per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
(c)(1)If a health insurer maintains a drug formulary grouped into tiers, the copayment of not more than ten dollars ($10) pursuant to subdivision (b) shall apply only to naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose that is in Tier 1 or Tier 2 or that is provided over-the-counter at an in-network pharmacy.
(2)A health insurer that maintains a drug formulary grouped into tiers shall include, for each of the insurers formularies, in Tiers 1 and 2 combined, at least two drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
(d)(1)Point-of-sale coverage for over-the-counter, FDA-approved naloxone hydrochloride or another drug or product approved by the FDA for over-the-counter complete or partial reversal of an opioid overdose shall be provided at in-network pharmacies.
(2)A health insurance policy may impose a limit on the quantity of over-the-counter, FDA-approved naloxone hydrochloride covered if a reasonable limit is established by the department in coordination with the Department of Managed Health Care.
(3)For purposes of this section, point-of-sale means the ability to charge only the applicable cost sharing amount for an over-the-counter, FDA-approved opioid reversal or partial reversal drug or product at the time of purchase.
(e)If a health insurance policy is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose cost sharing as specified in this section, unless not applying cost sharing would conflict with federal requirements for high deductible health plans.
(f)This section does not limit the provisions of Sections 10123.191, 10123.193, 10123.1932, 10123.197, and 10123.201 with respect to prescription naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose.
(g)Coverage provided pursuant to this section shall be provided consistent with guidance issued by the FDA in connection with drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
(h)A health insurance policy that provides coverage for prescription drugs pursuant to this section may require an insured to obtain naloxone hydrochloride or another drug or product approved by the FDA for the complete or partial reversal of an opioid overdose from a network provider, consistent with this chapter.
(i)The commissioner may issue guidance to insurers regarding compliance with this section. This guidance shall not be subject to the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The department shall consult with the Department of Managed Health Care in issuing the guidance specified in this subdivision.
(j)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 4.Section 14132.37 is added to the Welfare and Institutions Code, immediately following Section 14132.36, to read:14132.37.(a)Prescription or nonprescription naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of an opioid overdose shall be a covered benefit under the Medi-Cal program.
(b)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
The Legislature finds and declares all of the following:
(a)According to the United States Food and Drug Administration (FDA), naloxone hydrochloride is a medicine that can counter overdose effects when administered timely and that can help to reduce opioid overdose deaths.
(b)In November 2022, the FDA issued a Federal Register notice with a preliminary assessment of the safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use, in order to facilitate the development and approval of those products, including through a potential switch from prescription status to nonprescription status.
(c)In February 2023, an advisory committee to the FDA voted unanimously in favor of making Narcan, a naloxone hydrochloride nasal spray, available over the counter.
(d)In March 2023, the FDA approved Narcan for nonprescription use.
(e)The California Overdose Surveillance Dashboard, administered by the State Department of Public Health, contains the following data applicable to the state for 2021:
(1)Seven thousand one hundred seventy-five deaths were documented as relating to an opioid overdose. Of those deaths, 5,961 were documented as relating to a fentanyl overdose.
(2)Eight hundred forty-six deaths were associated with an opioid-related overdose for persons 24 years of age or younger. Of those deaths, 801 were associated with a fentanyl-related overdose.
(3)Twenty-one thousand sixteen emergency department (ED) visits were documented as relating to an opioid overdose. Of those ED visits, 5,644 were associated with a fentanyl-related overdose.
SEC. 2.Section 1374.198 is added to the Health and Safety Code, immediately following Section 1374.197, to read:1374.198.(a)A health care service plan contract that provides coverage for prescription drugs and that is issued, amended, delivered, or renewed on or after January 1, 2025, shall cover at least one product of each available dosage form for prescription or prescription and nonprescription naloxone hydrochloride or another drug and all other drugs or products approved by the United States Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose.
(b)A health care service plan contract that provides coverage for prescription drugs shall not impose any cost-sharing requirements, including a copayment copayment, coinsurance, or deductible, for coverage provided pursuant to this section exceeding ten dollars ($10) per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
(c)(1)If a health care service plan maintains a drug formulary grouped into tiers, the copayment of not more than ten dollars ($10) pursuant to subdivision (b) shall apply only to naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose that is in Tier 1 or Tier 2. 2 or that is provided over-the-counter at an in-network pharmacy.
(2)A health care service plan that maintains a drug formulary grouped into tiers shall include, for each of the plans formularies, in Tiers 1 and 2 combined, at least two drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
(d)(1)Point-of-sale coverage for over-the-counter, FDA-approved naloxone hydrochloride or another drug or product approved by the FDA for over-the-counter complete or partial reversal of an opioid overdose shall be provided at in-network pharmacies.
(2)A health care service plan contract may impose a limit on the quantity of over-the-counter, FDA-approved naloxone hydrochloride covered if a reasonable limit is established by the department in coordination with the Department of Insurance.
(3)For purposes of this section, point-of-sale means the ability to charge only the applicable cost sharing amount for an over-the-counter, FDA-approved opioid reversal or partial reversal drug or product at the time of purchase.
(e)If a health care service plan contract is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose cost sharing as specified in this section, unless not applying cost sharing would conflict with federal requirements for high deductible health plans.
(f)This section does not limit the provisions of Sections 1342.7, 1342.73, 1367.206, 1367.24, 1367.241, and 1367.244 with respect to prescription naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose.
(g)Coverage provided pursuant to this section shall be provided consistent with guidance issued by the FDA in connection with drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
(h)A health care service plan contract that provides coverage for prescription drugs pursuant to this section may require an enrollee to obtain naloxone hydrochloride or another drug or product approved by the FDA for the complete or partial reversal of an opioid overdose from a network provider, consistent with this chapter.
(i)This section does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14590) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.
(f)(j)The director may issue guidance to health care service plans regarding compliance with this section. This guidance shall not be subject to the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The department shall consult with the Department of Insurance in issuing the guidance specified in this subdivision.
(g)(k)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 3.Section 10127.22 is added to the Insurance Code, immediately following Section 10127.20, to read:10127.22.(a)A health insurance policy that provides coverage for prescription drugs and that is issued, amended, delivered, or renewed on or after January 1, 2025, shall cover at least one product of each available dosage form for prescription or prescription and nonprescription naloxone hydrochloride or another drug and all other drugs or products approved by the United States Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose.
(b)A health insurer insurance policy that provides coverage for prescription drugs shall not impose any cost-sharing requirements, including a copayment copayment, coinsurance, or deductible, for coverage provided pursuant to this section exceeding ten dollars ($10) per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
(c)(1)If a health insurer maintains a drug formulary grouped into tiers, the copayment of not more than ten dollars ($10) pursuant to subdivision (b) shall apply only to naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose that is in Tier 1 or Tier 2. 2 or that is provided over-the-counter at an in-network pharmacy.
(2)A health insurer that maintains a drug formulary grouped into tiers shall include, for each of the insurers formularies, in Tiers 1 and 2 combined, at least two drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
(d)(1)Point-of-sale coverage for over-the-counter, FDA-approved naloxone hydrochloride or another drug or product approved by the FDA for over-the-counter complete or partial reversal of an opioid overdose shall be provided at in-network pharmacies.
(2)A health insurance policy may impose a limit on the quantity of over-the-counter, FDA-approved naloxone hydrochloride covered if a reasonable limit is established by the department in coordination with the Department of Managed Health Care.
(3)For purposes of this section, point-of-sale means the ability to charge only the applicable cost sharing amount for an over-the-counter, FDA-approved opioid reversal or partial reversal drug or product at the time of purchase.
(e)If a health insurance policy is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose cost sharing as specified in this section, unless not applying cost sharing would conflict with federal requirements for high deductible health plans.
(f)This section does not limit the provisions of Sections 10123.191, 10123.193, 10123.1932, 10123.197, and 10123.201 with respect to prescription naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose.
(g)Coverage provided pursuant to this section shall be provided consistent with guidance issued by the FDA in connection with drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
(h)A health insurance policy that provides coverage for prescription drugs pursuant to this section may require an insured to obtain naloxone hydrochloride or another drug or product approved by the FDA for the complete or partial reversal of an opioid overdose from a network provider, consistent with this chapter.
(f)(i)The commissioner may issue guidance to insurers regarding compliance with this section. This guidance shall not be subject to the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The department shall consult with the Department of Managed Health Care in issuing the guidance specified in this subdivision.
(g)(j)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 4.Section 14132.37 is added to the Welfare and Institutions Code, immediately following Section 14132.36, to read:14132.37.(a)Prescription or nonprescription naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of an opioid overdose shall be a covered benefit under the Medi-Cal program.
(b)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
The Legislature finds and declares all of the following:
(a)According to the United States Food and Drug Administration (FDA), naloxone hydrochloride is a medicine that can counter overdose effects when administered timely and that can help to reduce opioid overdose deaths.
(b)In November 2022, the FDA issued a Federal Register notice with a preliminary assessment of the safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use, in order to facilitate the development and approval of those products, including through a potential switch from prescription status to nonprescription status.
(c)In February 2023, an advisory committee to the FDA voted unanimously in favor of making Narcan, a naloxone hydrochloride nasal spray, available over the counter.
(d)In March 2023, the FDA approved Narcan for nonprescription use.
(e)The California Overdose Surveillance Dashboard, administered by the State Department of Public Health, contains the following data applicable to the state for 2021:
(1)Seven thousand one hundred seventy-five deaths were documented as relating to an opioid overdose. Of those deaths, 5,961 were documented as relating to a fentanyl overdose.
(2)Eight hundred forty-six deaths were associated with an opioid-related overdose for persons 24 years of age or younger. Of those deaths, 801 were associated with a fentanyl-related overdose.
(3)Twenty-one thousand sixteen emergency department (ED) visits were documented as relating to an opioid overdose. Of those ED visits, 5,644 were associated with a fentanyl-related overdose.
SEC. 2.Section 1374.198 is added to the Health and Safety Code, immediately following Section 1374.197, to read:1374.198.(a)A health care service plan contract that is issued, amended, delivered, or renewed on or after January 1, 2024, or a contract offered in the individual or small group market on or after January 1, 2025, shall include coverage cover at least one product of each available dosage form for prescription or nonprescription naloxone hydrochloride or another drug approved by the United States Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose.
(b)A health care service plan contract shall not impose any cost-sharing requirements, including a copayment or deductible, for coverage provided pursuant to this section exceeding ten dollars ($10) per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
(c)If a health care service plan maintains a drug formulary grouped into tiers, the copayment of not more than ten dollars ($10) pursuant to subdivision (b) shall apply only to naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose that is in Tier 1 or Tier 2.
(d)(1)Point-of-sale coverage for over-the-counter, FDA-approved naloxone hydrochloride shall be provided at in-network pharmacies.
(2)A health care service plan contract may impose a limit on the quantity of over-the-counter, FDA-approved naloxone hydrochloride covered if a reasonable limit is established by the department in coordination with the Department of Insurance.
(c)(e)If a health care service plan contract is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose cost sharing as specified in this section, unless not applying cost sharing would conflict with federal requirements for high deductible health plans.
(f)The director may issue guidance to health care service plans regarding compliance with this section. This guidance shall not be subject to the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The department shall consult with the Department of Insurance in issuing the guidance specified in this subdivision.
(d)(g)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 3.Section 10127.22 is added to the Insurance Code, immediately following Section 10127.20, to read:10127.22.(a)A health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2024, or a policy offered in the individual or small group market on or after January 1, 2025, shall include coverage cover at least one product of each available dosage form for prescription or nonprescription naloxone hydrochloride or another drug approved by the United States Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose.
(b)A health insurer shall not impose any cost-sharing requirements, including a copayment or deductible, for coverage provided pursuant to this section exceeding ten dollars ($10) per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
(c)If a health insurer maintains a drug formulary grouped into tiers, the copayment of not more than ten dollars ($10) pursuant to subdivision (b) shall apply only to naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose that is in Tier 1 or Tier 2.
(d)(1)Point-of-sale coverage for over-the-counter, FDA-approved naloxone hydrochloride shall be provided at in-network pharmacies.
(2)A health insurance policy may impose a limit on the quantity of over-the-counter, FDA-approved naloxone hydrochloride covered if a reasonable limit is established by the department in coordination with the Department of Managed Health Care.
(c)(e)If a health insurance policy is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose cost sharing as specified in this section, unless not applying cost sharing would conflict with federal requirements for high deductible health plans.
(f)The commissioner may issue guidance to insurers regarding compliance with this section. This guidance shall not be subject to the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The department shall consult with the Department of Managed Health Care in issuing the guidance specified in this subdivision.
(d)(g)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 4.Section 14132.37 is added to the Welfare and Institutions Code, immediately following Section 14132.36, to read:14132.37.(a)Prescription or nonprescription naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of an opioid overdose shall be a covered benefit under the Medi-Cal program.
(b)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
The Legislature finds and declares all of the following:
(a)According to the United States Food and Drug Administration (FDA), naloxone hydrochloride is a medicine that can counter overdose effects when administered timely and that can help to reduce opioid overdose deaths.
(b)In November 2022, the FDA issued a Federal Register notice with a preliminary assessment of the safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use, in order to facilitate the development and approval of those products, including through a potential switch from prescription status to nonprescription status.
(c)In February 2023, an advisory committee to the FDA voted unanimously in favor of making Narcan, a naloxone hydrochloride nasal spray, available over the counter.
(d)The FDA is expected to make a final decision by the end of March 2023 on whether to approve In March 2023, the FDA approved Narcan for nonprescription use.
(e)The California Overdose Surveillance Dashboard, administered by the State Department of Public Health, contains the following data applicable to the state for 2021:
(1)Seven thousand one hundred seventy-five deaths were documented as relating to an opioid overdose. Of those deaths, 5,961 were documented as relating to a fentanyl overdose.
(2)Eight hundred forty-six deaths were associated with an opioid-related overdose for persons 24 years of age or younger. Of those deaths, 801 were associated with a fentanyl-related overdose.
(3)Twenty-one thousand sixteen emergency department (ED) visits were documented as relating to an opioid overdose. Of those ED visits, 5,644 were associated with a fentanyl-related overdose.
SEC. 2.Section 1374.198 is added to the Health and Safety Code, immediately following Section 1374.197, to read:1374.198.(a)A health care service plan contract that is issued, amended, delivered, or renewed on or after January 1, 2024, or a contract offered in the individual or small group market on or after January 1, 2025, shall include coverage for prescription or nonprescription naloxone hydrochloride, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration for treatment of an opioid overdose. A health care service plan contract shall not impose any cost-sharing requirements, including a copayment or deductible, for coverage provided pursuant to this section and shall cover the total cost of prescription or nonprescription naloxone hydrochloride. hydrochloride or another drug approved by the United States Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose.
(b)A health care service plan contract shall not impose any cost-sharing requirements, including a copayment or deductible, for coverage provided pursuant to this section exceeding ten dollars ($10) per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
(c)If a health care service plan contract is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose cost sharing as specified in this section, unless not applying cost sharing would conflict with federal requirements for high deductible health plans.
(d)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 3.Section 10127.22 is added to the Insurance Code, immediately following Section 10127.20, to read:10127.22.(a)A health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2024, or a policy offered in the individual or small group market on or after January 1, 2025, shall include coverage for prescription or nonprescription naloxone hydrochloride, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration for treatment of an opioid overdose. A health insurer shall not impose any cost-sharing requirements, including a copayment or deductible, for coverage provided pursuant to this section and shall cover the total cost of prescription or nonprescription naloxone hydrochloride. hydrochloride or another drug approved by the United States Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose.
(b)A health insurer shall not impose any cost-sharing requirements, including a copayment or deductible, for coverage provided pursuant to this section exceeding ten dollars ($10) per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
(c)If a health insurance policy is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose cost sharing as specified in this section, unless not applying cost sharing would conflict with federal requirements for high deductible health plans.
(d)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 4.Section 14132.37 is added to the Welfare and Institutions Code, immediately following Section 14132.36, to read:14132.37.(a)Prescription or nonprescription naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of an opioid overdose shall be a covered benefit under the Medi-Cal program, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration for treatment of an opioid overdose. The department shall not subject coverage provided pursuant to this section to any share-of-cost requirements and shall cover the total cost of prescription or nonprescription naloxone hydrochloride. program.
(b)This section shall remain in effect only until January 1, 2030, and as of that date is repealed.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
The Legislature finds and declares all of the following:
(a)According to the United States Food and Drug Administration (FDA), naloxone hydrochloride is a medicine that can counter overdose effects when administered timely and that can help to reduce opioid overdose deaths.
(b)In November 2022, the FDA issued a Federal Register notice with a preliminary assessment of the safety and effectiveness of certain naloxone hydrochloride drug products for nonprescription use, in order to facilitate the development and approval of those products, including through a potential switch from prescription status to nonprescription status.
(c)In February 2023, an advisory committee to the FDA voted unanimously in favor of making Narcan, a naloxone hydrochloride nasal spray, available over the counter.
(d)The FDA is expected to make a final decision by the end of March 2023 on whether to approve Narcan for nonprescription use.
(e)The California Overdose Surveillance Dashboard, administered by the State Department of Public Health, contains the following data applicable to the state for 2021:
(1)Seven thousand one hundred seventy-five deaths were documented as relating to an opioid overdose. Of those deaths, 5,961 were documented as relating to a fentanyl overdose.
(2)Eight hundred forty-six deaths were associated with an opioid-related overdose for persons 24 years of age or younger. Of those deaths, 801 were associated with a fentanyl-related overdose.
(3)Twenty-one thousand sixteen emergency department (ED) visits were documented as relating to an opioid overdose. Of those ED visits, 5,644 were associated with a fentanyl-related overdose.
SEC. 2.Section 1374.198 is added to the Health and Safety Code, immediately following Section 1374.197, to read:1374.198.A health care service plan contract that is issued, amended, delivered, or renewed on or after January 1, 2024, shall include coverage for prescription or nonprescription naloxone hydrochloride, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration for treatment of an opioid overdose. A health care service plan contract shall not impose any cost-sharing requirements, including a copayment or deductible, for coverage provided pursuant to this section and shall cover the total cost of prescription or nonprescription naloxone hydrochloride.
SEC. 3.Section 10127.22 is added to the Insurance Code, immediately following Section 10127.20, to read:10127.22.A health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2024, shall include coverage for prescription or nonprescription naloxone hydrochloride, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration for treatment of an opioid overdose. A health insurer shall not impose any cost-sharing requirements, including a copayment or deductible, for coverage provided pursuant to this section and shall cover the total cost of prescription or nonprescription naloxone hydrochloride.
SEC. 4.Section 14132.37 is added to the Welfare and Institutions Code, immediately following Section 14132.36, to read:14132.37.Prescription or nonprescription naloxone hydrochloride shall be a covered benefit under the Medi-Cal program, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration for treatment of an opioid overdose. The department shall not subject coverage provided pursuant to this section to any share-of-cost requirements and shall cover the total cost of prescription or nonprescription naloxone hydrochloride.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SECTION 1.Section 1797 of the Health and Safety Code is amended to read:1797.This division shall be known, and may be cited, as the Emergency Medical Services System and the Prehospital Emergency Medical Care Personnel Act.This division shall be known known, and may be cited cited, as the Emergency Medical Services System and the Prehospital Emergency Medical Care Personnel Act.
|
Date
|
Status
|
|---|---|
| Jan 30, 2024 | Consideration of Governor's veto stricken from file. |
| Jan 3, 2024 | Consideration of Governor's veto pending. |
| Oct 7, 2023 | Vetoed by Governor. |
| Sep 21, 2023 | Enrolled and presented to the Governor at 3:30 p.m. |
| Sep 13, 2023 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 80. Noes 0. Page 3408.). |
| Sep 12, 2023 | In Assembly. Concurrence in Senate amendments pending. |
| Sep 12, 2023 | Read third time. Passed. Ordered to the Assembly. (Ayes 38. Noes 0. Page 2649.). |
| Sep 11, 2023 | Read second time. Ordered to third reading. |
| Sep 8, 2023 | Read third time and amended. Ordered to second reading. |
| Sep 5, 2023 | Read second time. Ordered to third reading. |
| Sep 1, 2023 | Read second time and amended. Ordered returned to second reading. |
| Sep 1, 2023 | From committee: Amend, and do pass as amended. (Ayes 6. Noes 0.) (September 1). |
| Jul 10, 2023 | In committee: Referred to APPR. suspense file. |
| Jun 29, 2023 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 12. Noes 0.) (June 28). Re-referred to Com. on APPR. |
| Jun 12, 2023 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 7, 2023 | Referred to Com. on HEALTH. |
| May 26, 2023 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 25, 2023 | Read third time. Passed. Ordered to the Senate. (Ayes 77. Noes 0. Page 1757.) |
| May 18, 2023 | Read second time. Ordered to third reading. |
| May 18, 2023 | From committee: Do pass. (Ayes 15. Noes 0.) (May 18). |
| May 18, 2023 | Joint Rule 62(a), file notice suspended. (Page 1580.) |
| May 17, 2023 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 26, 2023 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 15. Noes 0.) (April 25). Re-referred to Com. on APPR. |
| Mar 20, 2023 | Re-referred to Com. on HEALTH. |
| Mar 16, 2023 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 16, 2023 | Referred to Com. on HEALTH. |
| Feb 16, 2023 | From printer. May be heard in committee March 18. |
| Feb 15, 2023 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 13, 2023 | AB 1060 Ortega Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Sep 12, 2023 | Assembly 3rd Reading AB1060 Ortega et al. By Wahab | Senate Floor |
Passed |
|
| Sep 1, 2023 | Do pass as amended | Senate Standing Committee on Appropriations |
Passed |
|
| Jul 10, 2023 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 28, 2023 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 25, 2023 | AB 1060 Ortega Assembly Third Reading | Assembly Floor |
Passed |
|
| May 18, 2023 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 25, 2023 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| AmericaS Health Insurance Plans | ** Against | |
| Asian Health Services | ** Support | |
| Association Of California Life And Health Insurance Companies | ** Against | |
| Attorney General Rob Bonta | ** Support | |
| California Academy Of Family Physicians | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Democratic Party | ** Support | |
| California Nurses Association | ** Support | |
| California Professional Firefighters | ** Support | |
| California Society Of Addiction Medicine | ** Support | |
| California State Board of Pharmacy | ** Support | |
| City of Soledad | ** Support | |
| County Behavioral Health Directors Association of California | ** Support | |
| County Health Executives Association Of California | ** Support | |
| County of Alameda Board of Supervisors | ** Support | |
| Davis Street Family Resource Center | ** Support | |
| Department Of Finance | ** Against | |
| Eden Health District | ** Support | |
| Eden Youth and Family Center | ** Support | |
| Ella Baker Center For Human Rights | ** Support | |
| Horizon Services, INC. | ** Support | |
| Initiate Justice | ** Support | |
| La Clinica de La Raza, Inc. | ** Support | |
| Latino Coalition for a Healthy California | ** Support | |
| League Of California Cities | ** Support | |
| Los Angeles Unified School District | ** Support | |
| National Health Law Program | ** Support | |
| Sister Warriors Freedom Coalition | ** Support | |
| western center on law & poverty | ** Support |
GOVERNOR'S VETO
GV Bill Id:AB 1060
Author:(Ortega)
As Enrolled Ver:September 18, 2023
2/3 vote
SUMMARY
Requires coverage of prescription or nonprescription naloxone hydrochloride (NH) and all other drugs or products under a health plan contract, health insurance policy, and the Medi-Cal program, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose. Prohibits a health plan contract or health insurance policy from imposing any cost-sharing requirements exceeding $10 per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
Senate Amendments
- Delay implementation to January 1, 2025, and require coverage of at least one product of each available dosage form for prescription or nonprescription NH.
- Prohibits cost sharing from exceeding $10 per package of NH or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
- Requires the copayment of not more than $10 to apply only to NH or another product approved by the FDA for the complete or partial reversal of an opioid overdose that is in Tier 1 or Tier 2 or that is provided over-the-counter at an in-network pharmacy, if a health plan or insurer maintains a drug formulary grouped into tiers. Requires a health plan or insurer that maintains a drug formulary grouped into tiers to include, for each of the plan's formularies, in Tiers 1 and 2 combined, at least two drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
- Requires point-of-sale coverage for over-the-counter, FDA-approved NH to be provided at in-network pharmacies.
- Authorizes a health plan contract or insurance policy to impose a limit on the quantity of over-the-counter, FDA-approved NH covered if a reasonable limit is established by the Department of Managed Health Care (DMHC) in coordination with the Department of Insurance (CDI).
- Prohibits a health plan contract or insurance policy that is a high deductible plan from imposing cost sharing requirements in conflict with federal requirements, as specified.
- Authorizes the DMHC Director or CDI Commissioner to issue guidance regarding compliance.
- Sunsets the provisions of this bill on January 1, 2030.
Governor’s Veto Message
This bill would require health plans to cover prescription and over the counter naloxone and all other FDA approved drugs for opioid overdose reversal, with a maximum of $10 cost sharing.
Combating the opioid crisis is one of my top priorities. I appreciate the author's shared commitment to this critical public health and public safety imperative. Together with the Legislature, we have invested more than $ l billion to combat overdoses, support those with opioid use disorder, raise awareness, and crack down on trafficking. Further, the 2023 Budget Act included $30 million for the CalRx Naloxone Access Initiative, to support partners in developing, manufacturing, procuring, and distributing a low-cost naloxone nasal product.
While I support providing access to opioid antagonists to individuals with opioid use disorder or other risk factors, this bill would exceed the state's set of essential health benefits (EHBs), which are established by the state's benchmark plan under the provisions of the federal Affordable Care Act (ACA). As such, this bill's mandate would require the state to defray the costs of coverage in Covered California. This would not only increase ongoing state General Fund costs, but it would set a new precedent by adding requirements that exceed the benchmark plan. A pattern of new coverage mandate bills like this could open the state to millions to billions of dollars in new costs to cover services relating to other health conditions. This creates uncertainty for our healthcare system's affordability.
COMMENTS
According to the California Health Benefits Review Program (CHBRP) NH is an opioid antagonist, meaning that it binds to opioid receptors throughout the body, thus reversing and blocking the effects of opioids. NH can be used for all opioids, including natural compound opiates (such as morphine, heroin, and/or codeine), semi-synthetic opioids (such as hydrocodone, oxycodone, and/or hydromorphone), and synthetic opioids (such as fentanyl, carfentanil, and/or tramadol). NH is only effective for opioid overdose and has no effect on other common overdoses such as methamphetamines, benzodiazepines, or alcohol.
- The Centers for Disease Control and Prevention (CDC) reports that over 150 people die every day from overdoses related to synthetic opioids like fentanyl. According to the CDC, from 2016 to 2017 only three states, California, Illinois, and Virginia experienced a statistically significant change in overdose death rates involving synthetic opioids from 2016 to 2017. Eighteen states reflected no significant change in overdose deaths and 25 states plus the District of Columbia remained stable. In stark contrast, the 2019-2020 figures reflect that 40 states and the District of Columbia experienced a statistically significant increase in opioid related deaths while only four states did not have a significant increase and only seven states remained stable.
- Reversing opioid overdoses. NH (Narcan) is an opioid antagonist that rapidly reverses an opioid overdose. It attaches to opioid receptors and reverses and blocks the effects of other opioids. NH can quickly restore normal breathing to a person if their breathing has slowed or stopped because of an opioid overdose. NH comes in two FDA-approved forms: injectable and prepackaged nasal spray.
- Narcan nasal spray was first approved by the FDA in 2015 as a prescription drug. According to the FDA, in accordance with a process to change the status of a drug from prescription to nonprescription, the manufacturer provided data demonstrating that the drug is safe and effective for use as directed in its proposed labeling. The manufacturer also showed that consumers can understand how to use the drug safely and effectively without the supervision of a healthcare professional. The application to approve Narcan nasal spray for over-the-counter (OTC) use was granted priority review status and was the subject of an advisory committee meeting in February 2023, where committee members voted unanimously to recommend it be approved for marketing without a prescription.
- On March 29, 2023 the FDA approved Narcan for nonprescription use. This is the first NH product approved for use without a prescription. This approval will allow this medication to be sold directly to consumers in drug stores, grocery stores, as well as online. According to an FDA Commissioner, "The approval of OTC NH nasal spray will help improve access to NH, increase the number of locations where it's available and help reduce opioid overdose deaths throughout the country. We encourage the manufacturer to make accessibility to the product a priority by making it available as soon as possible and at an affordable price." It is unknown when this product will become readily available for OTC purchase and what the cost will be.
- CHBRP analysis. CHBRP reviewed this bill and states the following in its analysis:
- Enrollees covered. This bill would apply to the health insurance of 24,853,000 California enrollees (64% of all Californians). This represents those who have commercial or CalPERS health insurance regulated by the DMHC and CDI and Medi-Cal beneficiaries enrolled in DMHC-regulated plans or county organized health systems.
- Impact on expenditures. Postmandate, 100% of the 24,982,000 enrollees will have coverage fully compliant with this bill, meaning prescription and nonprescription NH would be covered without cost sharing. Since there are no estimates available as to the utilization rate of nonprescription NH, as an illustrative example, CHBRP assumed 20% of enrollees with an opioid addiction would receive one kit of nonprescription NH postmandate and 5% of commercial and Medi-Cal enrollees with an opioid addiction would have one family member who would also receive one kit of nonprescription NH. CHBRP estimates that prescription NH (nasal sprays and injections) prescriptions will increase by 1,410 from 38,850 to 40,260, a 3.63% increase. Nonprescription NH (nasal sprays) covered by insurers will increase from 0 to 77,580. The increased utilization is driven both by the proposed legislation's removal of cost sharing as well as by removal of the need for a prescription. Since Medi-Cal plans do not have cost sharing, the prescription utilization rate for Medi-Cal enrollees remains unchanged postmandate. State expenditures for Medi-Cal would increase by $1,328,000, or 0.003%. This bill would increase total net annual expenditures by $9,218,000 or 0.006% for enrollees with DMHC-regulated plans and CDI-regulated policies.
- EHBs. Since prescription drugs are an EHB category, the portion of this bill that requires coverage of prescription NH does not exceed the definition of EHBs in California. It is unclear whether the requirement to provide coverage of nonprescription NH without cost sharing would exceed EHBs. Although medically necessary treatment for substance use disorder within applicable clinical guidelines is within the EHB standard, as is emergency care, the circumstances under which nonprescription NH may be obtained may not fall within these categories.
According to the Author
The danger of fentanyl to young kids is that it only takes two milligrams – smaller than a grain of rice – to end a life. NH saves lives by reversing opioid overdoses – but only if you can afford it. The author concludes that this bill will ensure that every parent, family member, or guardian can have access to this life-saving drug and protect their family members.
Arguments in Support
California's Attorney General writes that having NH more widely available is an important piece to addressing the opioid crisis. In California, there were 7,175 deaths related to an opioid overdose in 2021, and 5,961 of those deaths were specifically attributed to Fentanyl. Fentanyl is a powerful and potentially addictive synthetic opioid that is up to 50 times stronger than heroin. A small amount of fentanyl, just two milligrams, can result in overdose and potentially death. This opioid crisis is a multifaceted public health and safety issue. Addressing this crisis requires a thoughtful and strategic approach. The California Department of Justice (DOJ) works with local and federal law enforcement partners through the Fentanyl Enforcement Program to detect, deter, disrupt, and dismantle criminal fentanyl operations. DOJ's ongoing work to address the fentanyl crisis includes the seizure of over four million fentanyl pills and almost 900 pounds of fentanyl powder, and over 200 arrests through the DOJ's Bureau of Investigation and work with allied task forces throughout California since April 2021.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All ACA-compliant plans provide a robust package of EHBs in the large group, small business, and individual markets. In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates. The opposition states all of these bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options. The Department of Finance is opposed to this bill as it results in new General Fund and Managed Care Fund costs that are not included in the 2023-24 budget plan. These costs could also potentially increase health care premiums for consumers.
FISCAL COMMENTS
According to the Senate Appropriations Committee,
- Unknown ongoing costs, likely hundreds of thousands, for the DMHC for state operations (Managed Care Fund).
- Unknown costs in 2023-24 for the CDI for state operations (Insurance Fund).
- Unknown ongoing costs, likely low millions (General Fund and federal funds), for the Medi-Cal program to provide the benefit.
VOTES
ASM HEALTH: 15-0-0
YES: Wood, Waldron, Aguiar-Curry, Arambula, Boerner, Wendy Carrillo, Flora, Vince Fong, Maienschein, McCarty, Joe Patterson, Rodriguez, Santiago, Villapudua, Weber
ASM APPROPRIATIONS: 15-0-1
YES: Holden, Megan Dahle, Bryan, Calderon, Wendy Carrillo, Dixon, Mike Fong, Hart, Lowenthal, Mathis, Papan, Pellerin, Sanchez, Weber, Ortega
ABS, ABST OR NV: Robert Rivas
ASSEMBLY FLOOR: 77-0-3
YES: Addis, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Chen, Connolly, Megan Dahle, Davies, Dixon, Flora, Mike Fong, Vince Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Jim Patterson, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
ABS, ABST OR NV: Aguiar-Curry, Essayli, Mathis
SENATE FLOOR: 38-0-2
YES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Cortese, Dahle, Dodd, Durazo, Eggman, Glazer, Gonzalez, Hurtado, Jones, Laird, Limón, McGuire, Menjivar, Min, Newman, Nguyen, Niello, Ochoa Bogh, Padilla, Portantino, Roth, Rubio, Seyarto, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
ABS, ABST OR NV: Caballero, Grove
ASSEMBLY FLOOR: 80-0-0
YES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Chen, Connolly, Megan Dahle, Davies, Dixon, Essayli, Flora, Mike Fong, Vince Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones‑Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, Mathis, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Jim Patterson, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Luz Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
UPDATED
VERSION: September 18, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0002507
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1060
Author:(Ortega)
As Amended Ver:September 8, 2023
Majority vote
SUMMARY
Requires coverage of prescription or nonprescription naloxone hydrochloride (NH) and all other drugs or products under a health plan contract, health insurance policy, and the Medi-Cal program, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose. Prohibits a health plan contract or health insurance policy from imposing any cost-sharing requirements exceeding $10 per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
Senate Amendments
- Delay implementation to January 1, 2025, and require coverage of at least one product of each available dosage form for prescription or nonprescription NH.
- Prohibits cost sharing from exceeding $10 per package of NH or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
- Requires the copayment of not more than $10 to apply only to NH or another product approved by the FDA for the complete or partial reversal of an opioid overdose that is in Tier 1 or Tier 2 or that is provided over-the-counter at an in-network pharmacy, if a health plan or insurer maintains a drug formulary grouped into tiers. Requires a health plan or insurer that maintains a drug formulary grouped into tiers to include, for each of the plan’s formularies, in Tiers 1 and 2 combined, at least two drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
- Requires point-of-sale coverage for over-the-counter, FDA-approved NH to be provided at in-network pharmacies.
- Authorizes a health plan contract or insurance policy to impose a limit on the quantity of over-the-counter, FDA-approved NH covered if a reasonable limit is established by the Department of Managed Health Care (DMHC) in coordination with the Department of Insurance (CDI).
- Prohibits a health plan contract or insurance policy that is a high deductible plan from imposing cost sharing requirements in conflict with federal requirements, as specified.
- Authorizes the DMHC Director or CDI Commissioner to issue guidance regarding compliance.
- Sunsets the provisions of this bill on January 1, 2030.
COMMENTS
According to the California Health Benefits Review Program (CHBRP) NH is an opioid antagonist, meaning that it binds to opioid receptors throughout the body, thus reversing and blocking the effects of opioids. NH can be used for all opioids, including natural compound opiates (such as morphine, heroin, and/or codeine), semi-synthetic opioids (such as hydrocodone, oxycodone, and/or hydromorphone), and synthetic opioids (such as fentanyl, carfentanil, and/or tramadol). NH is only effective for opioid overdose and has no effect on other common overdoses such as methamphetamines, benzodiazepines, or alcohol.
- The Centers for Disease Control and Prevention (CDC) reports that over 150 people die every day from overdoses related to synthetic opioids like fentanyl. According to the CDC, from 2016 to 2017 only three states, California, Illinois, and Virginia experienced a statistically significant change in overdose death rates involving synthetic opioids from 2016 to 2017. Eighteen states reflected no significant change in overdose deaths and 25 states plus the District of Columbia remained stable. In stark contrast, the 2019-2020 figures reflect that 40 states and the District of Columbia experienced a statistically significant increase in opioid related deaths while only four states did not have a significant increase and only seven states remained stable.
- Reversing opioid overdoses. NH (Narcan) is an opioid antagonist that rapidly reverses an opioid overdose. It attaches to opioid receptors and reverses and blocks the effects of other opioids. NH can quickly restore normal breathing to a person if their breathing has slowed or stopped because of an opioid overdose. NH comes in two FDA-approved forms: injectable and prepackaged nasal spray.
- Narcan nasal spray was first approved by the FDA in 2015 as a prescription drug. According to the FDA, in accordance with a process to change the status of a drug from prescription to nonprescription, the manufacturer provided data demonstrating that the drug is safe and effective for use as directed in its proposed labeling. The manufacturer also showed that consumers can understand how to use the drug safely and effectively without the supervision of a healthcare professional. The application to approve Narcan nasal spray for over-the-counter (OTC) use was granted priority review status and was the subject of an advisory committee meeting in February 2023, where committee members voted unanimously to recommend it be approved for marketing without a prescription.
- On March 29, 2023 the FDA approved Narcan for nonprescription use. This is the first NH product approved for use without a prescription. This approval will allow this medication to be sold directly to consumers in drug stores, grocery stores, as well as online. According to an FDA Commissioner, "The approval of OTC NH nasal spray will help improve access to NH, increase the number of locations where it's available and help reduce opioid overdose deaths throughout the country. We encourage the manufacturer to make accessibility to the product a priority by making it available as soon as possible and at an affordable price." It is unknown when this product will become readily available for OTC purchase and what the cost will be.
- CHBRP analysis. CHBRP reviewed this bill and states the following in its analysis:
- Enrollees covered. This bill would apply to the health insurance of 24,853,000 California enrollees (64% of all Californians). This represents those who have commercial or CalPERS health insurance regulated by the DMHC and CDI and Medi-Cal beneficiaries enrolled in DMHC-regulated plans or county organized health systems.
- Impact on expenditures. Postmandate, 100% of the 24,982,000 enrollees will have coverage fully compliant with this bill, meaning prescription and nonprescription NH would be covered without cost sharing. Since there are no estimates available as to the utilization rate of nonprescription NH, as an illustrative example, CHBRP assumed 20% of enrollees with an opioid addiction would receive one kit of nonprescription NH postmandate and 5% of commercial and Medi-Cal enrollees with an opioid addiction would have one family member who would also receive one kit of nonprescription NH. CHBRP estimates that prescription NH (nasal sprays and injections) prescriptions will increase by 1,410 from 38,850 to 40,260, a 3.63% increase. Nonprescription NH (nasal sprays) covered by insurers will increase from 0 to 77,580. The increased utilization is driven both by the proposed legislation's removal of cost sharing as well as by removal of the need for a prescription. Since Medi-Cal plans do not have cost sharing, the prescription utilization rate for Medi-Cal enrollees remains unchanged postmandate. State expenditures for Medi-Cal would increase by $1,328,000, or 0.003%. This bill would increase total net annual expenditures by $9,218,000 or 0.006% for enrollees with DMHC-regulated plans and CDI-regulated policies.
- Essential Health Benefits (EHBs). Since prescription drugs are an EHB category, the portion of this bill that requires coverage of prescription NH does not exceed the definition of EHBs in California. It is unclear whether the requirement to provide coverage of nonprescription NH without cost sharing would exceed EHBs. Although medically necessary treatment for substance use disorder within applicable clinical guidelines is within the EHB standard, as is emergency care, the circumstances under which nonprescription NH may be obtained may not fall within these categories.
- Public health. CHBRP estimates this bill would result in increased distribution of NH, which would contribute to increased treatment of opioid overdoses and a potential reduction in mortality. This estimate is supported by evidence that use of NH is medically effective in reversing opioid overdose and an increase in distribution of NH. However, CHBRP is unable to quantify the extent to which reductions in mortality would occur due to uncertainties about the degree to which distribution of NH would occur postmandate. According to CHBRP, this bill would contribute to a decrease in fatalities from opioid overdose, although the extent to which this would occur is unknown.
- Long-term impacts. The long-term impact depends on the extent to which reductions in cost sharing and prescription requirements will lead to increased access and whether that increased access will lead to increased use of NH to treat opioid use overdose. People whose lives are saved with NH treatment may have different cost trajectories that those modeled in the short term. After an overdose, an enrollee may be seen by emergency medical personnel, seen in an emergency department, or seek treatment for an opioid use disorder. All of these actions would result in additional health expenditures over time.
According to the Author
The danger of fentanyl to young kids is that it only takes two milligrams – smaller than a grain of rice – to end a life. NH saves lives by reversing opioid overdoses – but only if you can afford it. The author concludes that this bill will ensure that every parent, family member, or guardian can have access to this life-saving drug and protect their family members.
Arguments in Support
California's Attorney General writes that having NH more widely available is an important piece to addressing the opioid crisis. In California, there were 7,175 deaths related to an opioid overdose in 2021, and 5,961 of those deaths were specifically attributed to Fentanyl. Fentanyl is a powerful and potentially addictive synthetic opioid that is up to 50 times stronger than heroin. A small amount of fentanyl, just two milligrams, can result in overdose and potentially death. This opioid crisis is a multifaceted public health and safety issue. Addressing this crisis requires a thoughtful and strategic approach. The California Department of Justice (DOJ) works with local and federal law enforcement partners through the Fentanyl Enforcement Program to detect, deter, disrupt, and dismantle criminal fentanyl operations. DOJ's ongoing work to address the fentanyl crisis includes the seizure of over four million fentanyl pills and almost 900 pounds of fentanyl powder, and over 200 arrests through the DOJ's Bureau of Investigation and work with allied task forces throughout California since April 2021.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All Patient Protection and Affordable Care Act (ACA)-compliant plans provide a robust package of EHBs in the large group, small business, and individual markets. In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates. The opposition states all of these bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options. The Department of Finance is opposed to this bill as it results in new General Fund and Managed Care Fund costs that are not included in the 2023-24 budget plan. These costs could also potentially increase health care premiums for consumers.
FISCAL COMMENTS
According to the Senate Appropriations Committee,
- Unknown ongoing costs, likely hundreds of thousands, for the DMHC for state operations (Managed Care Fund).
- Unknown costs in 2023-24 for the CDI for state operations (Insurance Fund).
- Unknown ongoing costs, likely low millions (General Fund and federal funds), for the Medi-Cal program to provide the benefit.
VOTES:
ASM HEALTH: 15-0-0
YES: Wood, Waldron, Aguiar-Curry, Arambula, Boerner, Wendy Carrillo, Flora, Vince Fong, Maienschein, McCarty, Joe Patterson, Rodriguez, Santiago, Villapudua, Weber
ASM APPROPRIATIONS: 15-0-1
YES: Holden, Megan Dahle, Bryan, Calderon, Wendy Carrillo, Dixon, Mike Fong, Hart, Lowenthal, Mathis, Papan, Pellerin, Sanchez, Weber, Ortega
ABS, ABST OR NV: Robert Rivas
ASSEMBLY FLOOR: 77-0-3
YES: Addis, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Chen, Connolly, Megan Dahle, Davies, Dixon, Flora, Mike Fong, Vince Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Jim Patterson, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
ABS, ABST OR NV: Aguiar-Curry, Essayli, Mathis
UPDATED
VERSION: September 8, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0002301
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 1060 |
THIRD READING
Bill No: AB 1060
Author: Ortega (D), et al.
Amended: 9/8/23 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 12-0, 6/28/23
AYES: Eggman, Nguyen, Glazer, Gonzalez, Grove, Hurtado, Limón, Menjivar, Roth, Rubio, Wahab, Wiener
SENATE APPROPRIATIONS COMMITTEE: 6-0, 9/1/23
AYES: Portantino, Jones, Ashby, Bradford, Wahab, Wiener
NO VOTE RECORDED: Seyarto
ASSEMBLY FLOOR: 77-0, 5/25/23 - See last page for vote
SUBJECT: Health care coverage: naloxone hydrochloride
SOURCE: Author
DIGEST:
- This bill requires a health plan contract or health insurance policy that provides coverage for prescription drugs and is issued, amended, delivered, or renewed on or after January 1, 2025, to include coverage for prescription and nonprescription naloxone hydrochloride and all other drugs or products approved by the U.S. Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose. This bill limits cost-sharing and coinsurance to not more than $10 per package, and, sunsets on January 1, 2030.
Senate Floor Amendments of 9/8/23:
- Limit the bill to those plans and insurers that provide coverage for prescription drugs;
- Expand the bill to include coverage of nonprescription naloxone hydrochloride and all other drugs or products approved by the FDA for opioid overdose reversals;
- Add a limitation on coinsurance charges of $10 per package and clarify the cost-sharing and coinsurance limit applies to over-the-counter opioid overdose reversal drugs obtained at a pharmacy that is in the plan’s or insurer’s network;
- Require coverage of at least two opioid overdose reversal drugs or products in plans or policies where a drug formulary is grouped into tiers;
- Define “point-of-sale” to mean the ability to charge only the applicable cost-sharing amount for an over-the-counter, FDA-approved opioid reversal or partial reversal drug or product at the time of purchase;
- Indicate that this bill does not limit specified prescription drug provisions of existing law;
- Require coverage provided pursuant to this bill to be provided consistent with related guidance issued by FDA;
- Authorize a plan or insurer to require an enrollee or insured to obtain an opioid overdose reversal drug or product from an in-network provider consistent with existing law; and,
- Exempt Medi-Cal managed care plans to the extent that the services are excluded from coverage under the Medi-Cal contract.
ANALYSIS: Existing law establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
This bill:
- Requires a health plan contract or health insurance policy that covers prescription drugs and is issued, amended, delivered, or renewed on or after January 1, 2025, to cover prescription and nonprescription naloxone hydrochloride or all other drugs or products approved by the FDA for the complete or partial reversal of an opioid overdose.
- Prohibits a health plan contract or insurance policy that provides coverage for prescription drugs from imposing any cost-sharing requirements, including a copayment, coinsurance, or deductible, exceeding $10 per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
- Requires if the plan or insurer maintains a drug formulary grouped into tiers, the copayment of not more than $10 to apply only to naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose that is in Tier 1 or 2 or that is provided over-the-counter at an in-network pharmacy.
- Requires point-of-sale coverage to be provided at in-network pharmacies.
- Permits a plan or insurer to impose a limit on the quantity of over-the-counter, FDA-approved naloxone hydrochloride covered if a reasonable limit is established by DMHC or CDI in coordination with each other.
- Authorizes DMHC or CDI to issue guidance regarding compliance, not subject to the Administrative Procedures Act, as specified. Requires DMHC and CDI to consult with each other in issuing the guidance.
- Prohibits if a health plan contract or insurance policy is a “high deductible health plan or HDHP” under federal definition, the contractor policy from imposing cost-sharing as specified in this bill, unless not applying cost-sharing would conflict with federal requirements for HDHPs.
- Sunsets this bill on January 1, 2030.
Comments
Naloxone. According to the California Department of Public Health (CDPH) website, naloxone is an opioid antagonist that works almost immediately to reverse opiate overdose and has few known adverse effects, no potential for abuse, and can be rapidly administered through intramuscular injection or nasal spray. Programs to train and equip bystanders, such as friends, family, and other non-health care providers, and drug users themselves, have gained momentum as an effective way to respond to and reverse an opioid overdose. On March 29, 2023, the FDA approved four milligram naloxone nasal spray for over-the-counter (OTC), nonprescription, use—the first naloxone product approved for use without a prescription. This action, according to the FDA, paves the way for the life-saving medication to reverse an opioid overdose to be sold directly to consumers in places like drug stores, convenience stores, grocery stores, and gas stations, as well as online. The timeline for availability and price of this OTC product is determined by the manufacturer. The FDA will work with all stakeholders to help facilitate the continued availability of naloxone nasal spray products during the time needed to implement the switch from prescription to OTC status, which may take months. Other formulations and dosages of naloxone will remain available by prescription only.
California Health Benefits Review Program (CHBRP) report. Key findings include:
- Opioid use disorder prevalence in California was 1.58% among people aged 12 years and older in 2021. In 2021, 7,175 Californians died from an opioid-related overdose, which was an increase of 119% from 2019. About 21,000 Californians were seen in emergency departments for opioid-related overdose in 2021 and over 5,000 Californians were hospitalized for opioid-related overdose. Research has shown that patients who are discharged from emergency departments after an opioid-related overdose are at a high risk for mortality. The one year mortality after an overdose ranged from 5.3% to 5.5%.
- Assumptions. Because there are no estimates available as to the utilization rate of nonprescription naloxone, as an illustrative example, CHBRP assumed 20% of enrollees with an opioid addiction would receive one kit of nonprescription naloxone postmandate and 5% of commercial and Medi-Cal enrollees with an opioid addiction would have one family member who would also receive one kit of nonprescription naloxone. Additionally, naloxone is frequently administered outside of the medical system. Enrollees in health savings account-qualified HDHPs would be required to meet their plan or policy deductible before cost-sharing would be limited to $10. As a simplifying assumption, CHBRP has assumed the deductible threshold for all enrollees in these plans is $1,600, which is the federal deductible threshold for plans or policies to be designated an HDHP in 2024. CHBRP assumes the unit cost of nonprescription naloxone would be $50, in accordance with the announcement from the manufacturer of Narcan. The unit cost of prescription naloxone was obtained through claims data.
- Coverage impacts and enrollees covered. Postmandate, 100% of the 24,982,000 enrollees will have coverage fully compliant with this bill, meaning prescription and nonprescription naloxone would be covered. Almost add (95.6%) of commercial and CalPERS enrollees in plans and policies regulated by DMHC or CDI have a pharmacy benefit. The remainder either don’t have a pharmacy benefit (1.2%) or the benefit is not regulated by DMHC and CDI (3.2%).
- Utilization. In Year 1, CHBRP estimates that use of prescription naloxone (nasal sprays and injections) would not increase. Average cost-sharing at baseline for prescription naloxone for enrollees in the large group market, CalPERS, and Medi-Cal is below the $10 cost-sharing limit, and therefore there would be no induced utilization as a result of lower cost-sharing due to this bill. Use of nonprescription naloxone (nasal sprays) covered by insurers will increase from 16,361 to 77,420 due to the coverage of nonprescription naloxone. The increased utilization is driven both by the proposed legislation’s reduction of cost-sharing as well as by removal of the need for a prescription. In Year 2, when the small group and individual markets would be required to implement this bill as amended, utilization of prescription and nonprescription naloxone would increase. An additional 12,510 enrollees would obtain prescription naloxone, while an additional 11,520 enrollees would obtain nonprescription naloxone.
- Medi-Cal. Furnishing naloxone is a covered pharmacist service under Medi-Cal.
- Impact on expenditures. In the illustrative example, this bill as amended on June 12, 2023, would increase total net annual expenditures by $3,467,000 or 0.002% in Year 1 and $3,732,000 in Year 2. In the illustrative example, it is estimated that this bill would increase premiums by about $4.1 million in Year 1 and $4.8 million in Year 2.
- Cost-sharing. There are two types of cost-sharing impacts for enrollees: the first is a reduction in cost-sharing for prescription naloxone, and the second is a reduction in expenses for previously noncovered nonprescription naloxone.
- In Year 1, enrollees would experience an increase in cost-sharing for covered benefits of $202,000 due to both new utilization and a shift of expenses from the noncovered category to the covered category. Expenses for noncovered benefits would decrease by $818,000.
- In Year 2, cost-sharing for covered benefits would increase by $336,000 and expenses for noncovered benefits would decrease by $1,386,000.
- Essential health benefits (EHB). Because prescription drugs are an EHB category, the portion of this bill that requires coverage of prescription naloxone would not require coverage for a new state benefit mandate and therefore does not exceed the definition of EHBs in California. It is unclear whether the requirement to provide coverage of nonprescription naloxone would exceed EHBs. Although medically necessary treatment for substance use disorder within applicable clinical guidelines is within the EHB standard, as is emergency care, the circumstances under which nonprescription naloxone may be obtained may not fall within these categories.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee:
- Unknown ongoing costs, likely hundreds of thousands, for the DMHC for state operations (Managed Care Fund).
- Unknown costs in 2023-24 for the CDI for state operations (Insurance Fund).
- Unknown ongoing costs, likely low millions (General Fund and federal funds), for the Medi-Cal program to provide the benefit.
SUPPORT: (Verified 9/8/23)
Attorney General Rob Bonta
Asian Health Services
California Academy of Family Physicians
California Democratic Party
California Nurses Association
California Professional Firefighters
California Society of Addiction Medicine
California State Board of Pharmacy
City of Soledad
County Behavioral Health Directors Association of California
County Health Executives Association of California
County of Alameda Board of Supervisors
Davis Street Family Resource Center
Eden Health District
Eden Youth and Family Center
Ella Baker Center for Human Rights
Horizon Services, Inc.
Initiate Justice
La Clinica De La Raza, Inc.
Latino Coalition for A Healthy California
League of California Cities
Los Angeles Unified School District
National Health Law Program
Sister Warriors Freedom Coalition
Western Center on Law & Poverty
OPPOSITION: (Verified 9/8/23)
America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
Department of Finance
ARGUMENTS IN SUPPORT: The County of Alameda Board of Supervisors writes that this bill’s goal to approve the use of naloxone hydrochloride for non-prescribed users has the potential to save thousands of lives from overdose, especially under the Medi-Cal program. The out-of-pocket cost of Narcan at a pharmacy is over $100 for two doses of the nasal spray, which is unaffordable for the average Californian. By making prescription and over-the-counter naloxone widely accessible to residents this bill can potentially save thousands of lives from fatal opioid overdoses. The City of Soledad writes that since 2018 there have been over 70 non-fatal overdoses, in many instances, naloxone was administered and helped to save lives and in the past two years, five deaths were related to opioid overdose, specifically fentanyl. Narcan saves lives and is an important piece to addressing the opioid crisis. The League of California Cities (Cal Cities) writes that this is one of a slate of bills that could help save countless lives across our state. Cal Cities supports a number of critically needed fentanyl and other substance use-related legislation. These measures would stem the tide of illicit substance-related deaths in California and bring relief to the many communities mourning tragic, preventable deaths. The Los Angeles Unified School District writes fentanyl and methamphetamine related overdose deaths continue to rise exponentially in Los Angeles County and the rest of the nation at an alarming rate. Research shows that the availability of naloxone along with overdose education is effective at decreasing overdoses and death–and will save lives. This bill supports public health, school safety efforts, and remains consistent with Los Angeles Unified’ s ongoing efforts in dealing with the Opioid crisis. As the largest school district in California, our student population faces many socioeconomic challenges, with approximately 60% being eligible for Medi-Cal. This bill’s accessibility to a lifesaving health provision will help ensure all of us in the school community are doing our part to ensure a safe school environment.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write in opposition to this along with 22 other health insurance mandate bills. State mandates increase costs of coverage – especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Benefit mandates that do not promote evidence-based medicine can lead to lower quality care, over- or misutilization of services, and higher costs for treatments that may be ineffective, less safe, or higher cost than other, new or trusted services. California is rightly focused on achieving both universal coverage and cost containment at a time when the national conversation has shifted toward lower costs through less comprehensive options. The Department of Finance is opposed to this bill as it results in new General Fund and MCF costs that are not included in the 2023-24 budget plan. These costs could also potentially increase health care premiums for consumers.
ASSEMBLY FLOOR: 77-0, 5/25/23
AYES: Addis, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Chen, Connolly, Megan Dahle, Davies, Dixon, Flora, Mike Fong, Vince Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Jim Patterson, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
NO VOTE RECORDED: Aguiar-Curry, Essayli, Mathis
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
9/11/23 12:49:58
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 1060 |
THIRD READING
Bill No: AB 1060
Author: Ortega (D), et al.
Amended: 9/1/23 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 12-0, 6/28/23
AYES: Eggman, Nguyen, Glazer, Gonzalez, Grove, Hurtado, Limón, Menjivar, Roth, Rubio, Wahab, Wiener
SENATE APPROPRIATIONS COMMITTEE: 6-0, 9/1/23
AYES: Portantino, Jones, Ashby, Bradford, Wahab, Wiener
NO VOTE RECORDED: Seyarto
ASSEMBLY FLOOR: 77-0, 5/25/23 - See last page for vote
SUBJECT: Health care coverage: naloxone hydrochloride
SOURCE: Author
DIGEST:
- This bill requires a health plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2024, or a contract or policy offered in the individual or small group market on or after January 1, 2025, to include coverage for prescription or nonprescription naloxone hydrochloride or another drug approved by the U.S. Food and Drug Administration for the complete or partial reversal of an opioid overdose. This bill limits cost-sharing to not more than $10 per package, and, sunsets this bill on January 1, 2030.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Authorizes licensed health care providers to issue a standing order for the distribution or the administration of naloxone to a person at risk of overdose, or family members, friends, or other persons in a position to assist a person at risk of an opioid-related overdose. Requires a person who is prescribed or possesses naloxone pursuant to a standing order to receive training, as specified. [CIV §1714.22, et seq.]
- Authorizes a pharmacist to furnish a U.S. Food and Drug Administration (FDA)-approved opioid antagonist in accordance with standardized procedures or protocols, as specified, and prohibits a pharmacist from allowing the person to whom the drug is being furnished to waive the consultation. [BPC §4052.01]
- Requires a prescriber when prescribing an opioid or benzodiazepine medication to a patient, to offer the patient a prescription for naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of opioid-induced respiratory depression when specified conditions are present such as the patient is at risk for opioid overdose. Requires the provider to provide education consistent with existing standard of care, as specified. [BPC §741]
This bill:
- Requires a health plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2025, or a contract or policy offered in the individual or small group market on or after January 1, 2025, to cover at least one product of each available dosage form for prescription or nonprescription naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
- Prohibits a health plan contract or insurance policy from imposing any cost-sharing requirements, including a copayment or deductible, exceeding $10 per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
- Requires if the plan or insurer maintains a drug formulary grouped into tiers, the copayment of not more than $10 dollars to apply only to naloxone hydrochloride or another product approved by the FDA for the complete or partial reversal of an opioid overdose that is in Tier 1 or 2.
- Requires point-of-sale coverage to be provided at in-network pharmacies.
- Permits a plan or insurer to impose a limit on the quantity of over-the-counter, FDA-approved naloxone hydrochloride covered if a reasonable limit is established by DMHC or CDI in coordination with each other.
- Authorizes DMHC or CDI to issue guidance regarding compliance, not subject to the Administrative Procedures Act, as specified. Requires DMHC and CDI to consult with each other in issuing the guidance.
- Prohibits if a health plan contract or insurance policy is a “high deductible health plan or HDHP” under federal definition, the contractor policy from imposing cost-sharing as specified in this bill, unless not applying cost-sharing would conflict with federal requirements for HDHPs.
- Requires prescription or nonprescription naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose to be a covered benefit under the Medi-Cal program.
- Sunsets this bill on January 1, 2030.
Comments
According to the author, it only takes two milligrams, smaller than a grain of rice, to end a life. Naloxone saves lives by reversing opioid overdoses but only if you can afford it. This bill will ensure that every parent, family member, or guardian can have access to this life-saving drug and protect their family members.
Naloxone. According to the California Department of Public Health (CDPH) website, naloxone is an opioid antagonist that works almost immediately to reverse opiate overdose and has few known adverse effects, no potential for abuse, and can be rapidly administered through intramuscular injection or nasal spray. Programs to train and equip bystanders, such as friends, family, and other non-health care providers, and drug users themselves, have gained momentum as an effective way to respond to and reverse an opioid overdose. On March 29, 2023, the FDA approved four milligram naloxone nasal spray for over-the-counter (OTC), nonprescription, use—the first naloxone product approved for use without a prescription. This action, according to the FDA, paves the way for the life-saving medication to reverse an opioid overdose to be sold directly to consumers in places like drug stores, convenience stores, grocery stores, and gas stations, as well as online. The timeline for availability and price of this OTC product is determined by the manufacturer. The FDA will work with all stakeholders to help facilitate the continued availability of naloxone nasal spray products during the time needed to implement the switch from prescription to OTC status, which may take months. Other formulations and dosages of naloxone will remain available by prescription only.
California Health Benefits Review Program (CHBRP) report. Key findings include:
- Opioid use disorder prevalence in California was 1.58% among people aged 12 years and older in 2021. In 2021, 7,175 Californians died from an opioid-related overdose, which was an increase of 119% from 2019. About 21,000 Californians were seen in emergency departments for opioid-related overdose in 2021 and over 5,000 Californians were hospitalized for opioid-related overdose. Research has shown that patients who are discharged from emergency departments after an opioid-related overdose are at a high risk for mortality. The one year mortality after an overdose ranged from 5.3% to 5.5%.
- Assumptions. Because there are no estimates available as to the utilization rate of nonprescription naloxone, as an illustrative example, CHBRP assumed 20% of enrollees with an opioid addiction would receive one kit of nonprescription naloxone postmandate and 5% of commercial and Medi-Cal enrollees with an opioid addiction would have one family member who would also receive one kit of nonprescription naloxone. Additionally, naloxone is frequently administered outside of the medical system. Enrollees in health savings account-qualified HDHPs would be required to meet their plan or policy deductible before cost-sharing would be limited to $10. As a simplifying assumption, CHBRP has assumed the deductible threshold for all enrollees in these plans is $1,600, which is the federal deductible threshold for plans or policies to be designated an HDHP in 2024. CHBRP assumes the unit cost of nonprescription naloxone would be $50, in accordance with the announcement from the manufacturer of Narcan. The unit cost of prescription naloxone was obtained through claims data.
- Coverage impacts and enrollees covered. Postmandate, 100% of the 24,982,000 enrollees will have coverage fully compliant with this bill, meaning prescription and nonprescription naloxone would be covered. Almost add (95.6%) of commercial and CalPERS enrollees in plans and policies regulated by DMHC or CDI have a pharmacy benefit. The remainder either don’t have a pharmacy benefit (1.2%) or the benefit is not regulated by DMHC and CDI (3.2%).
- Utilization. In Year 1, CHBRP estimates that use of prescription naloxone (nasal sprays and injections) would not increase. Average cost-sharing at baseline for prescription naloxone for enrollees in the large group market, CalPERS, and Medi-Cal is below the $10 cost-sharing limit, and therefore there would be no induced utilization as a result of lower cost-sharing due to this bill. Use of nonprescription naloxone (nasal sprays) covered by insurers will increase from 16,361 to 77,420 due to the coverage of nonprescription naloxone. The increased utilization is driven both by the proposed legislation’s reduction of cost-sharing as well as by removal of the need for a prescription. In Year 2, when the small group and individual markets would be required to implement this bill as amended, utilization of prescription and nonprescription naloxone would increase. An additional 12,510 enrollees would obtain prescription naloxone, while an additional 11,520 enrollees would obtain nonprescription naloxone.
- Medi-Cal. Furnishing naloxone is a covered pharmacist service under Medi-Cal.
- Impact on expenditures. In the illustrative example, this bill as amended on June 12, 2023, would increase total net annual expenditures by $3,467,000 or 0.002% in Year 1 and $3,732,000 in Year 2. In the illustrative example, it is estimated that this bill would increase premiums by about $4.1 million in Year 1 and $4.8 million in Year 2. The distribution of the impact on premiums (and Medi-Cal expenditures) is as follows:
- Year 1 increases:
- Total premiums for commercial employers purchasing large group health insurance would increase by $569,000, or 0.001%.
- Total employer premium expenditures for CalPERS HMOs would increase by $56,000, or 0.001%.
- State expenditures for Medi-Cal would increase by $3,298,000, or 0.008%.
- Enrollee contributions toward premiums for group insurance would increase by $160,000, or 0.001%.
- Year 2 increases:
- Total premiums for commercial employers purchasing small or large group health insurance would increase by $760,000.
- Total premiums for purchasers of individual market health insurance would increase by $320,000.
- Enrollee contributions toward premiums for group insurance would increase by $336,000.
- Year 1 increases:
- Cost-sharing. There are two types of cost-sharing impacts for enrollees: the first is a reduction in cost-sharing for prescription naloxone, and the second is a reduction in expenses for previously noncovered nonprescription naloxone.
- In Year 1, enrollees would experience an increase in cost-sharing for covered benefits of $202,000 due to both new utilization and a shift of expenses from the noncovered category to the covered category. Expenses for noncovered benefits would decrease by $818,000.
- In Year 2, cost-sharing for covered benefits would increase by $336,000 and expenses for noncovered benefits would decrease by $1,386,000.
- Essential health benefits (EHB). Because prescription drugs are an EHB category, the portion of this bill that requires coverage of prescription naloxone would not require coverage for a new state benefit mandate and therefore does not exceed the definition of EHBs in California. It is unclear whether the requirement to provide coverage of nonprescription naloxone would exceed EHBs. Although medically necessary treatment for substance use disorder within applicable clinical guidelines is within the EHB standard, as is emergency care, the circumstances under which nonprescription naloxone may be obtained may not fall within these categories.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee:
- Unknown ongoing costs, likely hundreds of thousands, for the DMHC for state operations (Managed Care Fund).
- Unknown costs in 2023-24 for the CDI for state operations (Insurance Fund).
- Unknown ongoing costs, likely low millions (General Fund and federal funds), for the Medi-Cal program to provide the benefit.
SUPPORT: (Verified 8/17/23)
Attorney General Rob Bonta
Asian Health Services
California Academy of Family Physicians
California Democratic Party
California Nurses Association
California Professional Firefighters
California Society of Addiction Medicine
California State Board of Pharmacy
City of Soledad
County Behavioral Health Directors Association of California
County Health Executives Association of California
County of Alameda Board of Supervisors
Davis Street Family Resource Center
Eden Health District
Eden Youth and Family Center
Ella Baker Center for Human Rights
Horizon Services, INC.
Initiate Justice
La Clinica De La Raza, INC.
Latino Coalition for A Healthy California
League of California Cities
Los Angeles Unified School District
National Health Law Program
Sister Warriors Freedom Coalition
Western Center on Law & Poverty
OPPOSITION: (Verified 8/17/23)
America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
Department of Finance
ARGUMENTS IN SUPPORT: The County of Alameda Board of Supervisors writes that this bill’s goal to approve the use of naloxone hydrochloride for non-prescribed users has the potential to save thousands of lives from overdose, especially under the Medi-Cal program. The out-of-pocket cost of Narcan at a pharmacy is over $100 for two doses of the nasal spray, which is unaffordable for the average Californian. By making prescription and over-the-counter naloxone widely accessible to residents this bill can potentially save thousands of lives from fatal opioid overdoses. The City of Soledad writes that since 2018 there have been over 70 non-fatal overdoses, in many instances, naloxone was administered and helped to save lives and in the past two years, five deaths were related to opioid overdose, specifically fentanyl. Narcan saves lives and is an important piece to addressing the opioid crisis. The League of California Cities (Cal Cities) writes that this is one of a slate of bills that could help save countless lives across our state. Cal Cities supports a number of critically needed fentanyl and other substance use-related legislation. These measures would stem the tide of illicit substance-related deaths in California and bring relief to the many communities mourning tragic, preventable deaths. The Los Angeles Unified School District writes fentanyl and methamphetamine related overdose deaths continue to rise exponentially in Los Angeles County and the rest of the nation at an alarming rate. Research shows that the availability of naloxone along with overdose education is effective at decreasing overdoses and death–and will save lives. This bill supports public health, school safety efforts, and remains consistent with Los Angeles Unified’ s ongoing efforts in dealing with the Opioid crisis. As the largest school district in California, our student population faces many socioeconomic challenges, with approximately 60% being eligible for Medi-Cal. This bill’s accessibility to a lifesaving health provision will help ensure all of us in the school community are doing our part to ensure a safe school environment.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write in opposition to this along with 22 other health insurance mandate bills. State mandates increase costs of coverage – especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Benefit mandates that do not promote evidence-based medicine can lead to lower quality care, over- or misutilization of services, and higher costs for treatments that may be ineffective, less safe, or higher cost than other, new or trusted services. California is rightly focused on achieving both universal coverage and cost containment at a time when the national conversation has shifted toward lower costs through less comprehensive options. The Department of Finance is opposed to this bill as it results in new General Fund and MCF costs that are not included in the 2023-24 budget plan. These costs could also potentially increase health care premiums for consumers.
ASSEMBLY FLOOR: 77-0, 5/25/23
AYES: Addis, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Chen, Connolly, Megan Dahle, Davies, Dixon, Flora, Mike Fong, Vince Fong, Friedman, Gabriel, Gallagher, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lackey, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Jim Patterson, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
NO VOTE RECORDED: Aguiar-Curry, Essayli, Mathis
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
9/2/23 16:58:20
**** END ****
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anthony Portantino, Chair
2023 - 2024 Regular Session
AB 1060 (Ortega) - Health care coverage: naloxone hydrochloride
Version: June 12, 2023 | Policy Vote: HEALTH 12 - 0 |
Urgency: No | Mandate: Yes |
Hearing Date: September 1, 2023 | Consultant: Agnes Lee |
Bill Summary:
AB 1060 would require a health plan or insurer to include coverage for prescription or nonprescription naloxone hydrochloride or another drug approved by the U.S. Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose; and would limit patient cost-sharing to not more than $10 per package.
*********** ANALYSIS ADDENDUM – SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on September 1, 2023
Fiscal Impact:
- Unknown ongoing costs, likely hundreds of thousands, for the Department of Managed Health Care (DMHC) for state operations (Managed Care Fund).
- Unknown costs in 2023-24 for the California Department of Insurance (CDI) for state operations (Insurance Fund).
- Unknown ongoing costs, likely low millions (General Fund and federal funds), for the Medi-Cal program to provide the benefit.
Author Amendments:
Author amendments provide further specification of requirements related to health plans/insurers, including: delayed implementation, coverage of products, cost-sharing requirements, and over-the-counter products.
-- END --
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anthony Portantino, Chair
2023 - 2024 Regular Session
AB 1060 (Ortega) - Health care coverage: naloxone hydrochloride
Version: June 12, 2023 | Policy Vote: HEALTH 12 - 0 |
Urgency: No | Mandate: Yes |
Hearing Date: July 10, 2023 | Consultant: Agnes Lee |
Bill Summary:
AB 1060 would require a health plan or insurer to include coverage for prescription or nonprescription naloxone hydrochloride or another drug approved by the U.S. Food and Drug Administration (FDA) for the complete or partial reversal of an opioid overdose; and would limit patient cost-sharing to not more than $10 per package.
Fiscal Impact:
- The Department of Managed Health Care (DMHC) estimates costs to be approximately $147,000 in 2023-24, $705,000 in 2024-25, and $671,000 in 2025-26 and annually thereafter for state operations (Managed Care Fund).
- The California Department of Insurance (CDI) estimates costs of $3,000 in 2023-24 for state operations (Insurance Fund).
- Unknown, ongoing costs, likely low millions (General Fund and federal funds), for the Medi-Cal program to provide the benefit.
Background:
The DMHC regulates health plans under the Knox-Keene Act and the CDI regulates health insurance. Current law requires every health plan and disability insurance policy that provides hospital, medical, or surgical coverage to provide coverage for medically necessary treatment of mental health and substance use disorders, under the same terms and conditions applied to other medical conditions, as specified. Current law defines “medically necessary treatment of mental health or substance use disorder” to include that the service or product is in accordance with generally accepted standards of mental health or substance use disorder care, clinically appropriate in terms of type, frequency, extent, site, and duration.
The health plan or insurer must base any medical necessity determination or the utilization review criteria that the plan, and any entity acting on the plan’s behalf, applies to determine the medical necessity of health care services and benefits for the diagnosis, prevention, and treatment of mental health and substance use disorders on current generally accepted standards of mental health and substance use disorder care, as specified. Also, the health plan or insurer must apply the criteria and guidelines set forth in the most recent versions of treatment criteria developed by the nonprofit professional association for the relevant clinical specialty in conducting utilization review of all covered health care services and benefits for the diagnosis, prevention, and treatment of mental health and substance use disorders in children, adolescents, and adults.
Naloxone hydrochloride is an opioid antagonist, meaning that it binds to opioid receptors throughout the body, thus reversing and blocking the effects of opioids. Naloxone hydrochloride can be used for all opioids, including natural compound opiates (such as morphine, heroin, and/or codeine), semi-synthetic opioids (such as hydrocodone, oxycodone, and/or hydromorphone), and synthetic opioids (such as fentanyl, carfentanil, and/or tramadol). Naloxone hydrochloride is only effective for opioid overdose and has no effect on other common overdoses such as methamphetamines, benzodiazepines, or alcohol.
Proposed Law:
Specific provisions of the bill would:
- Require a health plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2024, or a contract or policy offered in the individual or small group market on or after January 1, 2025, to include coverage for prescription or nonprescription naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
- Prohibit a health plan contract or insurance policy from imposing any cost-sharing requirements, including a copayment or deductible, exceeding $10 per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
- Prohibit, if a health plan contract or insurance policy is a “high deductible health plan or HDHP” under federal definition, the contractor policy from imposing cost-sharing as specified in this bill, unless not applying cost-sharing would conflict with federal requirements for HDHPs.
- Require prescription or nonprescription naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose to be a covered benefit under the Medi-Cal program.
- Sunset the provisions on January 1, 2030.
Staff Comments:
The California Health Benefits Review Program (CHBRP) analysis of AB 1060 (amended June 12, 2023) estimates that total net annual expenditures would increase by $3,467,000 in year one and $3,732,000 in year two. This includes an increase of $56,000 for CalPERS health plan premiums and $3,298,000 for the Medi-Cal program in year one.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Susan Talamantes Eggman, Chair
BILL NO: AB 1060
AUTHOR: | Ortega | ||
VERSION: | June 12, 2023 | ||
HEARING DATE: | June 28, 2023 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Health care coverage: naloxone hydrochloride
SUMMARY:
- Requires a health plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2024, or a contract or policy offered in the individual or small group market on or after January 1, 2025, to include coverage for prescription or nonprescription naloxone hydrochloride or another drug approved by the U.S. Food and Drug Administration for the complete or partial reversal of an opioid overdose. Limits cost-sharing to not more than $10 per package, and, sunsets this bill on January 1, 2030.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Authorizes licensed health care providers to issue a standing order for the distribution or the administration of naloxone to a person at risk of overdose, or family members, friends, or other persons in a position to assist a person at risk of an opioid-related overdose. Requires a person who is prescribed or possesses naloxone pursuant to a standing order to receive training, as specified. [CIV §1714.22, et seq.]
- Authorizes a pharmacist to furnish a U.S. Food and Drug Administration (FDA)-approved opioid antagonist in accordance with standardized procedures or protocols, as specified, and prohibits a pharmacist from allowing the person to whom the drug is being furnished to waive the consultation. [BPC §4052.01]
- Requires a prescriber when prescribing an opioid or benzodiazepine medication to a patient, to offer the patient a prescription for naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of opioid-induced respiratory depression when specified conditions are present such as the patient is at risk for opioid overdose. Requires the provider to provide education consistent with existing standard of care, as specified. [BPC §741]
- Requires every disability insurance policy and health plan that provides hospital, medical, or surgical coverage to provide coverage for medically necessary treatment of mental health and substance use disorders, under the same terms and conditions applied to other medical conditions, as specified. [INS §10144.5 and HSC §1374.72]
- Defines “medically necessary treatment of mental health or substance use disorder” to include that the service or product is in accordance with generally accepted standards of mental health or substance use disorder care, clinically appropriate in terms of type, frequency, extent, site, and duration. [HSC §1374.72 and INS §10144.5]
- Requires a health plan or insurer that provides hospital, medical, or surgical coverage to base any medical necessity determination or the utilization review criteria on current generally accepted standards of mental health and substance use disorder care, as specified. [HSC §1374.72 and INS §10144.5]
- Requires a health plan or insurer that provides hospital, medical, or surgical coverage to base any medical necessity determination or the utilization review criteria that the plan, and any entity acting on the plan’s behalf, applies to determine the medical necessity of health care services and benefits for the diagnosis, prevention, and treatment of mental health and substance use disorders on current generally accepted standards of mental health and substance use disorder care, as specified. Requires a health plan or insurer to apply the criteria and guidelines set forth in the most recent versions of treatment criteria developed by the nonprofit professional association for the relevant clinical specialty in conducting utilization review of all covered health care services and benefits for the diagnosis, prevention, and treatment of mental health and substance use disorders in children, adolescents, and adults. [HSC §1374.721 and INS §10144.52]
This bill:
- Requires a health plan contract or health insurance policy that is issued, amended, delivered, or renewed on or after January 1, 2024, or a contract or policy offered in the individual or small group market on or after January 1, 2025, to include coverage for prescription or nonprescription naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
- Prohibits a health plan contract or insurance policy from imposing any cost-sharing requirements, including a copayment or deductible, exceeding $10 per package of naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose.
- Prohibits if a health plan contract or insurance policy is a “high deductible health plan or HDHP” under federal definition, the contractor policy from imposing cost-sharing as specified in this bill, unless not applying cost-sharing would conflict with federal requirements for HDHPs.
- Requires prescription or nonprescription naloxone hydrochloride or another drug approved by the FDA for the complete or partial reversal of an opioid overdose to be a covered benefit under the Medi-Cal program.
- Sunsets this bill on January 1, 2030.
FISCAL EFFECT:
According to the Assembly Appropriations Committee:
CDI estimates costs of $3,000 in fiscal year (FY) 2023-24 (Insurance Fund).
DMHC estimates costs of approximately $147,000 in FY 2023-24, $705,000 in FY 2024-25, and $671,000 in FY 2025-26 and annually thereafter (Managed Care Fund). These costs would be incurred by different units within DMHC as follows: a) the Help Center will need to address an increase in provider and consumer complaints; b) the Office of Enforcement will need to address additional enforcement referrals; and, c) the Office of Technology and Innovation will need to license software (Managed Care Fund).
See revised California Health Benefit Review Program (CHBRP) estimate in comment 5) below that reflects the June 12, 2023 amendments.
PRIOR VOTES:
Assembly Floor: | 77 - 0 |
Assembly Appropriations Committee: | 15 - 0 |
Assembly Health Committee: | 15 - 0 |
COMMENTS:
- Author’s statement. According to the author, it only takes two milligrams, smaller than a grain of rice, to end a life. Naloxone saves lives by reversing opioid overdoses but only if you can afford it. This bill will ensure that every parent, family member, or guardian can have access to this life-saving drug and protect their family members.
- Naloxone. According to the California Department of Public Health (CDPH) website, naloxone is an opioid antagonist that works almost immediately to reverse opiate overdose and has few known adverse effects, no potential for abuse, and can be rapidly administered through intramuscular injection or nasal spray. Programs to train and equip bystanders, such as friends, family, and other non-health care providers, and drug users themselves, have gained momentum as an effective way to respond to and reverse an opioid overdose. On March 29, 2023, the FDA approved four milligram naloxone nasal spray for over-the-counter (OTC), nonprescription, use—the first naloxone product approved for use without a prescription. This action, according to the FDA, paves the way for the life-saving medication to reverse an opioid overdose to be sold directly to consumers in places like drug stores, convenience stores, grocery stores, and gas stations, as well as online. The timeline for availability and price of this OTC product is determined by the manufacturer. The FDA will work with all stakeholders to help facilitate the continued availability of naloxone nasal spray products during the time needed to implement the switch from prescription to OTC status, which may take months. Other formulations and dosages of naloxone will remain available by prescription only.
- Statewide standing order for naloxone distribution. CDPH issued a statewide standing order for naloxone in June 2018. The order allows organizations and entities, including K-12 schools, colleges, and universities, to distribute naloxone to a person who is at risk of experiencing an overdose or an individual in a position to assist an at-risk person. Staff of community organizations and other entities distributing naloxone under the statewide standing order are required to receive training, and are also required to provide training to individuals who receive naloxone from them. Organizations may apply to use the statewide standing order and meet certain terms and conditions. A separate distribution program administered through DHCS allows various entities to apply for and obtain naloxone at no cost.
- Naloxone Distribution Project (NDP). The NDP aims to reduce opioid overdose deaths through the provision of free naloxone. Entities can apply to DHCS to have naloxone shipped directly to their address. Since it began in October 2018, the NDP has distributed more than 2,200,000 kits of naloxone, which have been used to reverse more than 140,000 overdoses. The NDP receives State General Funds and opioid settlement funds from the Janssen and Distributors Settlement Agreements. Eligible entities include:
- Law enforcement such as police departments, county jails, and probation;
- Fire, EMS, and first responders;
- Schools and universities;
- County public health and behavioral health departments; and,
- Community organizations, such as harm reduction organizations or community opioid coalitions.
- CHBRP analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Key findings include:
- Opioid use disorder prevalence in California was 1.58% among people aged 12 years and older in 2021. In 2021, 7,175 Californians died from an opioid-related overdose, which was an increase of 119% from 2019. About 21,000 Californians were seen in emergency departments for opioid-related overdose in 2021 and over 5,000 Californians were hospitalized for opioid-related overdose. Research has shown that patients who are discharged from emergency departments after an opioid-related overdose are at a high risk for mortality. The one year mortality after an overdose ranged from 5.3% to 5.5%.
- Assumptions. Because there are no estimates available as to the utilization rate of nonprescription naloxone, as an illustrative example, CHBRP assumed 20% of enrollees with an opioid addiction would receive one kit of nonprescription naloxone postmandate and 5% of commercial and Medi-Cal enrollees with an opioid addiction would have one family member who would also receive one kit of nonprescription naloxone. Additionally, naloxone is frequently administered outside of the medical system. Enrollees in health savings account-qualified HDHPs would be required to meet their plan or policy deductible before cost-sharing would be limited to $10. As a simplifying assumption, CHBRP has assumed the deductible threshold for all enrollees in these plans is $1,600, which is the federal deductible threshold for plans or policies to be designated an HDHP in 2024. CHBRP assumes the unit cost of nonprescription naloxone would be $50, in accordance with the announcement from the manufacturer of Narcan. The unit cost of prescription naloxone was obtained through claims data.
- Coverage impacts and enrollees covered. Postmandate, 100% of the 24,982,000 enrollees will have coverage fully compliant with this bill, meaning prescription and nonprescription naloxone would be covered. Almost add (95.6%) of commercial and CalPERS enrollees in plans and policies regulated by DMHC or CDI have a pharmacy benefit. The remainder either don’t have a pharmacy benefit (1.2%) or the benefit is not regulated by DMHC and CDI (3.2%).
- Utilization. In Year 1, CHBRP estimates that use of prescription naloxone (nasal sprays and injections) would not increase. Average cost-sharing at baseline for prescription naloxone for enrollees in the large group market, CalPERS, and Medi-Cal is below the $10 cost-sharing limit, and therefore there would be no induced utilization as a result of lower cost-sharing due to this bill. Use of nonprescription naloxone (nasal sprays) covered by insurers will increase from 16,361 to 77,420 due to the coverage of nonprescription naloxone. The increased utilization is driven both by the proposed legislation’s reduction of cost-sharing as well as by removal of the need for a prescription. In Year 2, when the small group and individual markets would be required to implement this bill as amended, utilization of prescription and nonprescription naloxone would increase. An additional 12,510 enrollees would obtain prescription naloxone, while an additional 11,520 enrollees would obtain nonprescription naloxone.
- Medi-Cal. Furnishing naloxone is a covered pharmacist service under Medi-Cal.
- Impact on expenditures. In the illustrative example, this bill as amended on June 12, 2023, would increase total net annual expenditures by $3,467,000 or 0.002% in Year 1 and $3,732,000 in Year 2. In the illustrative example, it is estimated that this bill would increase premiums by about $4.1 million in Year 1 and $4.8 million in Year 2. The distribution of the impact on premiums (and Medi-Cal expenditures) is as follows:
- Year 1 increases:
- Total premiums for commercial employers purchasing large group health insurance would increase by $569,000, or 0.001%.
- Total employer premium expenditures for CalPERS HMOs would increase by $56,000, or 0.001%.
- State expenditures for Medi-Cal would increase by $3,298,000, or 0.008%.
- Enrollee contributions toward premiums for group insurance would increase by $160,000, or 0.001%.
- Year 2 increases:
- Total premiums for commercial employers purchasing small or large group health insurance would increase by $760,000.
- Total premiums for purchasers of individual market health insurance would increase by $320,000.
- Enrollee contributions toward premiums for group insurance would increase by $336,000.
- Year 1 increases:
- Cost-sharing. There are two types of cost-sharing impacts for enrollees: the first is a reduction in cost-sharing for prescription naloxone, and the second is a reduction in expenses for previously noncovered nonprescription naloxone.
- In Year 1, enrollees would experience an increase in cost-sharing for covered benefits of $202,000 due to both new utilization and a shift of expenses from the noncovered category to the covered category. Expenses for noncovered benefits would decrease by $818,000.
- In Year 2, cost-sharing for covered benefits would increase by $336,000 and expenses for noncovered benefits would decrease by $1,386,000.
- Public health. In the first year postmandate, CHBRP estimates this bill would result in increased distribution of naloxone, which would contribute to increased treatment of opioid overdoses and a potential reduction in mortality. This estimate is supported by evidence that use of naloxone is medically effective in reversing opioid overdose and an increase in distribution of naloxone. However, CHBRP is unable to quantify the extent to which reductions in mortality would occur due to uncertainties about the degree to which distribution of naloxone would occur postmandate. It stands to reason that this bill would contribute to a decrease in fatalities from opioid overdose, although the extent to which this would occur is unknown.
- Essential health benefits (EHB). Because prescription drugs are an EHB category, the portion of this bill that requires coverage of prescription naloxone would not require coverage for a new state benefit mandate and therefore does not exceed the definition of EHBs in California. It is unclear whether the requirement to provide coverage of nonprescription naloxone would exceed EHBs. Although medically necessary treatment for substance use disorder within applicable clinical guidelines is within the EHB standard, as is emergency care, the circumstances under which nonprescription naloxone may be obtained may not fall within these categories.
- Opioid use disorder prevalence in California was 1.58% among people aged 12 years and older in 2021. In 2021, 7,175 Californians died from an opioid-related overdose, which was an increase of 119% from 2019. About 21,000 Californians were seen in emergency departments for opioid-related overdose in 2021 and over 5,000 Californians were hospitalized for opioid-related overdose. Research has shown that patients who are discharged from emergency departments after an opioid-related overdose are at a high risk for mortality. The one year mortality after an overdose ranged from 5.3% to 5.5%.
- Related legislation. SB 234 (Portantino, Hurtado, and Umberg) requires schools, college campuses, stadiums, concert venues, and amusement parks to, at all times, maintain unexpired doses of naloxone hydrochloride or any other opioid antagonist. Requires these entities to ensure that at least two employees are aware of the location of the naloxone or other opioid antagonist. SB 234 is set to be heard on June 28, 2023 in the Assembly Education Committee.
SB 641 (Roth) requires DHCS, as part of NDP, to make all FDA-approved formulations and dosage strengths of naloxone or another opioid antagonist that are indicated for the emergency treatment of known or suspected opioid overdose available to eligible NDP applicants to the extent that federal funding is not jeopardized. SB 641 is pending in the Senate Rules Committee.
SB 10 (Cortese) adds a protocol to the list of requirements for a comprehensive school safety plan in the event a pupil is suffering or is reasonably believed to be suffering from an opioid overdose. Requires California Department of Education (CDE), in collaboration with the California Health and Human Services Agency, to establish the State Working Group on Fentanyl Education in Schools to promote public education, awareness, and prevention of fentanyl overdoses, with the outreach aimed at staff and pupils in schools. SB 10 is set to be heard in the Assembly Education Committee on June 28, 2023.
SB 472 (Hurtado) requires each individual public school operated by a school district, county offices of education (COE), or charter school to maintain at least two doses of naloxone or another opioid antagonist, and to report to CDE and DHCS on or before July 31, 2024, and annually thereafter, certain information regarding opioid antagonists. SB 472 was held on the Senate Appropriations Committee Suspense File.
AB 19 (Joe Patterson, Matt Haney, and Liz Ortega) requires each public school operated by a local educational agency (LEA) and a COE, or charter school to maintain at least two doses of naloxone or another opioid antagonist on its campus. AB 19 is pending in the Senate Appropriations Committee.
AB 24 (Haney) requires a bar, gas station, public library, or residential hotel (collectively, “facility”) that receives an opioid antagonist kit (kit) from the CDPH to place the kit in an area of the facility that is readily accessible only by employees. The bill requires CDPH to compile and publish a list of counties experiencing an overdose crisis, create a poster with instructions on how to use the opioid antagonist, and to provide the kits, free of charge, to as many facilities as possible in the listed counties. AB 24 was held on the Assembly Appropriations Suspense File.
- Prior legislation. SB 367 (Hurtado, Chapter 218, Statutes of 2022), requires each community college, California State University campus, and requests University of California campuses with on-campus health centers to distribute opioid overdose reversal medication in accordance with the statewide standing order issued by the State Public Health Officer and to participate in the NDP.
AB 1748 (Mayes, Chapter 557, Statues of 2016) authorizes school districts to provide an emergency opioid antagonist to school nurses or trained personnel and authorizes a school nurse or trained personnel to administer an opioid antagonist to a person suffering from an opioid overdose.
- Support. Alameda County writes that this bill’s goal to approve the use of naloxone hydrochloride for non-prescribed users has the potential to save thousands of lives from overdose, especially under the Medi-Cal program. The out-of-pocket cost of Narcan at a pharmacy is over $100 for two doses of the nasal spray, which is unaffordable for the average Californian. By making prescription and over-the-counter naloxone widely accessible to residents this bill can potentially save thousands of lives from fatal opioid overdoses. The City of Soldedad writes that since 2018 there have been over 70 non-fatal overdoses, in many instances, naloxone was administered and helped to save lives and in the past two years, five deaths were related to opioid overdose, specifically fentanyl. Narcan saves lives and is an important piece to addressing the opioid crisis. The League of California Cities (Cal Cities) writes that this is one of a slate of bills that could help save countless lives across our state. Cal Cities supports a number of critically needed fentanyl and other substance use-related legislation. These measures would stem the tide of illicit substance-related deaths in California and bring relief to the many communities mourning tragic, preventable deaths. The Los Angeles Unified School District writes fentanyl and methamphetamine related overdose deaths continue to rise exponentially in Los Angeles County and the rest of the nation at an alarming rate. Research shows that the availability of naloxone along with overdose education is effective at decreasing overdoses and death–and will save lives. This bill supports public health, school safety efforts, and remains consistent with Los Angeles Unified’ s ongoing efforts in dealing with the Opioid crisis. As the largest school district in California, our student population faces many socioeconomic challenges, with approximately 60% being eligible for Medi-Cal. This bill’s accessibility to a lifesaving health provision will help ensure all of us in the school community are doing our part to ensure a safe school environment.
- Opposition. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write in opposition to this along with 22 other health insurance mandate bills. These bills include mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost-sharing and limit utilization management, which have similar cost impacts as coverage mandates. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. State mandates increase costs of coverage – especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Benefit mandates that do not promote evidence-based medicine can lead to lower quality care, over- or misutilization of services, and higher costs for treatments that may be ineffective, less safe, or higher cost than other, new or trusted services. California is rightly focused on achieving both universal coverage and cost containment at a time when the national conversation has shifted toward lower costs through less comprehensive options.
SUPPORT AND OPPOSITION:
Support: Asian Health Services
Attorney General Rob Bonta
California Academy of Family Physicians
California Nurses Association
California Professional Firefighters
California Society of Addiction Medicine
City of Soledad
County Behavioral Health Directors Association of California
County Health Executives Association of California
County of Alameda Board of Supervisors
Eden Health District
Eden Youth and Family Center
Ella Baker Center for Human Rights
Horizon Services, INC.
Initiate Justice
La Clinica De La Raza, INC.
Latino Coalition for A Healthy California
League of California Cities
National Health Law Program
Sister Warriors Freedom Coalition
Western Center on Law & Poverty
Oppose: America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1060
Author:(Ortega)
As Amended Ver:March 16, 2023
Majority vote
SUMMARY
Requires coverage of prescription or nonprescription naloxone hydrochloride (NH) under a health plan contract, health insurance policy, and the Medi-Cal program, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration (FDA) for treatment of an opioid overdose. Prohibits a health plan contract or health insurance policy from imposing any cost-sharing requirements.
Major Provisions
COMMENTS
According to the California Health Benefits Review Program (CHBRP) NH is an opioid antagonist, meaning that it binds to opioid receptors throughout the body, thus reversing and blocking the effects of opioids. NH can be used for all opioids, including natural compound opiates (such as morphine, heroin, and/or codeine), semi-synthetic opioids (such as hydrocodone, oxycodone, and/or hydromorphone), and synthetic opioids (such as fentanyl, carfentanil, and/or tramadol). NH is only effective for opioid overdose and has no effect on other common overdoses such as methamphetamines, benzodiazepines, or alcohol.
- The Centers for Disease Control and Prevention (CDC) reports that over 150 people die every day from overdoses related to synthetic opioids like fentanyl. According to the CDC, from 2016 to 2017 only three states, California, Illinois, and Virginia experienced a statistically significant change in overdose death rates involving synthetic opioids from 2016 to 2017. Eighteen states reflected no significant change in overdose deaths and 25 states plus the District of Columbia remained stable. In stark contrast, the 2019-2020 figures reflect that 40 states and the District of Columbia experienced a statistically significant increase in opioid related deaths while only four states did not have a significant increase and only seven states remained stable.
- Reversing opioid overdoses. NH (Narcan) is an opioid antagonist that rapidly reverses an opioid overdose. It attaches to opioid receptors and reverses and blocks the effects of other opioids. NH can quickly restore normal breathing to a person if their breathing has slowed or stopped because of an opioid overdose. NH comes in two FDA-approved forms: injectable and prepackaged nasal spray.
Narcan nasal spray was first approved by the FDA in 2015 as a prescription drug. According to the FDA, in accordance with a process to change the status of a drug from prescription to nonprescription, the manufacturer provided data demonstrating that the drug is safe and effective for use as directed in its proposed labeling. The manufacturer also showed that consumers can understand how to use the drug safely and effectively without the supervision of a healthcare professional. The application to approve Narcan nasal spray for over-the-counter (OTC) use was granted priority review status and was the subject of an advisory committee meeting in February 2023, where committee members voted unanimously to recommend it be approved for marketing without a prescription.
On March 29, 2023 the FDA approved Narcan for nonprescription use. This is the first NH product approved for use without a prescription. This approval will allow this medication to be sold directly to consumers in drug stores, grocery stores, as well as online. According to an FDA Commissioner, “The approval of OTC NH nasal spray will help improve access to NH, increase the number of locations where it's available and help reduce opioid overdose deaths throughout the country. We encourage the manufacturer to make accessibility to the product a priority by making it available as soon as possible and at an affordable price.” It is unknown when this product will become readily available for OTC purchase and what the cost will be.
- CHBRP analysis. CHBRP reviewed AB 1060 and states the following in its analysis:
- Enrollees covered. This bill would apply to the health insurance of 24,853,000 California enrollees (64% of all Californians). This represents those who have commercial or CalPERS health insurance regulated by the Department of Managed Health Care (DMHC) and California Department of Insurance (CDI) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans or county organized health systems.
- Impact on expenditures. Postmandate, 100% of the 24,982,000 enrollees will have coverage fully compliant with this bill, meaning prescription and nonprescription NH would be covered without cost sharing. Since there are no estimates available as to the utilization rate of nonprescription NH, as an illustrative example, CHBRP assumed 20% of enrollees with an opioid addiction would receive one kit of nonprescription NH postmandate and 5% of commercial and Medi-Cal enrollees with an opioid addiction would have one family member who would also receive one kit of nonprescription NH. CHBRP estimates that prescription NH (nasal sprays and injections) prescriptions will increase by 1,410 from 38,850 to 40,260, a 3.63% increase. Nonprescription NH (nasal sprays) covered by insurers will increase from 0 to 77,580. The increased utilization is driven both by the proposed legislation's removal of cost sharing as well as by removal of the need for a prescription. Since Medi-Cal plans do not have cost sharing, the prescription utilization rate for Medi-Cal enrollees remains unchanged postmandate. State expenditures for Medi-Cal would increase by $1,328,000, or 0.003%. This bill would increase total net annual expenditures by $9,218,000 or 0.006% for enrollees with DMHC-regulated plans and CDI-regulated policies.
- Essential Health Benefits (EHBs). Since prescription drugs are an EHB category, the portion of this bill that requires coverage of prescription NH does not exceed the definition of EHBs in California. It is unclear whether the requirement to provide coverage of nonprescription NH without cost sharing would exceed EHBs. Although medically necessary treatment for substance use disorder within applicable clinical guidelines is within the EHB standard, as is emergency care, the circumstances under which nonprescription NH may be obtained may not fall within these categories.
- Public health. CHBRP estimates this bill would result in increased distribution of NH, which would contribute to increased treatment of opioid overdoses and a potential reduction in mortality. This estimate is supported by evidence that use of NH is medically effective in reversing opioid overdose and an increase in distribution of NH. However, CHBRP is unable to quantify the extent to which reductions in mortality would occur due to uncertainties about the degree to which distribution of NH would occur postmandate. According to CHBRP, this bill would contribute to a decrease in fatalities from opioid overdose, although the extent to which this would occur is unknown.
- Long-term impacts. The long-term impact depends on the extent to which reductions in cost sharing and prescription requirements will lead to increased access and whether that increased access will lead to increased use of NH to treat opioid use overdose. People whose lives are saved with NH treatment may have different cost trajectories that those modeled in the short term. After an overdose, an enrollee may be seen by emergency medical personnel, seen in an emergency department, or seek treatment for an opioid use disorder. All of these actions would result in additional health expenditures over time.
According to the Author
The danger of fentanyl to young kids is that it only takes two milligrams – smaller than a grain of rice – to end a life. NH saves lives by reversing opioid overdoses – but only if you can afford it. The author concludes that this bill will ensure that every parent, family member, or guardian can have access to this life-saving drug and protect their family members.
Arguments in Support
California's Attorney General writes that having NH more widely available is an important piece to addressing the opioid crisis. In California, there were 7,175 deaths related to an opioid overdose in 2021, and 5,961 of those deaths were specifically attributed to Fentanyl. Fentanyl is a powerful and potentially addictive synthetic opioid that is up to 50 times stronger than heroin. A small amount of fentanyl, just two milligrams, can result in overdose and potentially death. This opioid crisis is a multifaceted public health and safety issue. Addressing this crisis requires a thoughtful and strategic approach. The California Department of Justice (DOJ) works with local and federal law enforcement partners through the Fentanyl Enforcement Program to detect, deter, disrupt, and dismantle criminal fentanyl operations. DOJ's ongoing work to address the fentanyl crisis includes the seizure of over four million fentanyl pills and almost 900 pounds of fentanyl powder, and over 200 arrests through the DOJ's Bureau of Investigation and work with allied task forces throughout California since April 2021.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All Patient Protection and Affordable Care Act (ACA)-compliant plans provide a robust package of EHBs in the large group, small business, and individual markets. In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates. The opposition states all of these bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options.
FISCAL COMMENTS
According to the Assembly Appropriations Committee:
- CDI estimates costs of $3,000 in fiscal year (FY) 2023-24 (Insurance Fund).
- The Department of Managed Health Care (DMHC) estimates costs of approximately $147,000 in FY 2023-24, $705,000 in FY 2024-25, and $671,000 in FY 2025-26 and annually thereafter (Managed Care Fund). These costs would be incurred by different units within DMHC as follows: a) the Help Center will need to address an increase in provider and consumer complaints; b) the Office of Enforcement will need to address additional enforcement referrals; and, c) the Office of Technology and Innovation will need to license software (Managed Care Fund).
- CHBRP estimates ongoing costs to the Department of Health Care Services for the bill's Medi-Cal requirements of $1.3 million (General Fund, federal funds). (Notes on CHBRP's assumptions are in the comments, below.)
- CHBRP estimates total premiums for CalPERS health plans will increase by $340,000 annually; a substantial, but unknown, portion of those premiums are paid by the state (General Fund, special funds).
- While this bill reduces the amount enrollees will have to pay for naloxone by a total of $860,000, CHBRP estimates this bill also increases total health plan and insurance expenditures across all payers – public and private – by $10.1 million, for a total net increase in costs of $9.2 million annually.
VOTES
ASM HEALTH: 15-0-0
YES: Wood, Waldron, Aguiar-Curry, Arambula, Boerner, Wendy Carrillo, Flora, Vince Fong, Maienschein, McCarty, Joe Patterson, Rodriguez, Santiago, Villapudua, Weber
ASM APPROPRIATIONS: 15-0-1
YES: Holden, Megan Dahle, Bryan, Calderon, Wendy Carrillo, Dixon, Mike Fong, Hart, Lowenthal, Mathis, Papan, Pellerin, Sanchez, Weber, Ortega
ABS, ABST OR NV: Robert Rivas
UPDATED
VERSION: March 16, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0000772
Date of Hearing: May 17, 2023
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Chris Holden, Chair
ABPCA Bill Id:AB 1060
Author:(Ortega) – As Amended Ver:March 16, 2023
Policy Committee: | Health | Vote: | 15 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires a health insurance policy or a health care service plan to include coverage for prescription or nonprescription naloxone hydrochloride (naloxone), if that medication is approved for prescription or nonprescription use, respectively, by the U.S. Food and Drug Administration (FDA) for treatment of an opioid overdose. The bill requires the health insurance policy or health plan to cover the total cost of naloxone without imposing any cost-sharing requirements. This bill also requires the Medi-Cal program to include naloxone as a covered benefit, with coverage for the total cost of the naloxone.
FISCAL EFFECT:
- The California Department of Insurance estimates costs of $3,000 in fiscal year (FY) 2023-24 (Insurance Fund).
- The Department of Managed Health Care (DMHC) estimates costs of approximately $147,000 in FY 2023-24, $705,000 in FY 2024-25, and $671,000 in FY 2025-26 and annually thereafter (Managed Care Fund). These costs would be incurred by different units within DMHC as follows: (a) the Help Center will need to address an increase in provider and consumer complaints; (b) the Office of Enforcement will need to address additional enforcement referrals; and (c) the Office of Technology and Innovation will need to license software (Managed Care Fund).
- The California Health Benefits Review Program (CHBRP) estimates ongoing costs to the Department of Health Care Services (DHCS) for the bill’s Medi-Cal requirements of $1.3 million (General Fund, federal funds). (Notes on CHBRP’s assumptions are in the comments, below.)
- CHBRP estimates total premiums for CalPERS health plans will increase by $340,000 annually; a substantial, but unknown, portion of those premiums are paid by the state (General Fund, special funds).
- While this bill reduces the amount enrollees will have to pay for naloxone by a total of $860,000, CHBRP estimates this bill also increases total health plan and insurance expenditures across all payers – public and private – by $10.1 million, for a total net increase in costs of $9.2 million annually.
COMMENTS:
- Purpose. According to the author:
As a mom, I think about the danger of fentanyl to my kids every day. It only takes 2 milligrams―smaller than a grain of rice―to end a life. Naloxone saves lives by reversing opioid overdoses―but only if you can afford it. AB 1060 will ensure that every parent, family member, or guardian can have access to this life-saving drug and protect their family members.
- Naloxone. Naloxone is an opioid antagonist, meaning it binds to opioid receptors throughout the body, thus reversing and blocking the effects of opioids. Naloxone can be used for all opioids, including natural compound opiates (such as morphine, heroin, and codeine), semi-synthetic opioids (such as hydrocodone, oxycodone, and hydromorphone), and synthetic opioids (such as fentanyl and carfentanil). Naloxone is only effective for opioid overdose and has no effect on other common overdoses such as methamphetamines, benzodiazepines, or alcohol. Naloxone is safe to use, without significant harmful effects, according to the National Institutes of Health.
In March, FDA approved Narcan (naloxone) for over-the-counter use. The approval means naloxone could be sold in places such as convenience stores, grocery stores and vending machines, in addition to drugstores. In April, Emergent BioSolutions, manufacturer of Narcan, announced it plans to price Narcan at less than $50 for two doses. - CHBRP Report. Because there are no estimates available as to the utilization rate of nonprescription naloxone, as an illustrative example, CHBRP assumed 20% of enrollees with an opioid addiction would receive one kit of nonprescription naloxone and 5% of commercial and MediCal enrollees with an opioid addiction would have one family member who would also receive one kit of nonprescription naloxone.
CHBRP estimates AB 1060 would result in increased distribution of naloxone, which would contribute to increased treatment of opioid overdoses and a potential reduction in mortality, although the extent to which this would occur is unknown.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 25, 2023
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 1060
Author:((Ortega) – As Amended Ver:March 16, 2023
SUBJECT: Health care coverage: naloxone hydrochloride.
SUMMARY: Requires coverage of prescription or nonprescription naloxone hydrochloride (NH) under a health plan contract, health insurance policy, and the Medi-Cal program, if that medication is approved, for prescription or nonprescription use, respectively, by the United States Food and Drug Administration (FDA) for treatment of an opioid overdose. Prohibits a health plan contract or health insurance policy from imposing any cost-sharing requirements. Specifically, this bill:
- Requires coverage of prescription or nonprescription NH under a health plan contract or health insurance policy, issued, amended, delivered, or renewed on or after January 1, 2024, if that medication is approved, for prescription or nonprescription use, respectively, by the FDA for treatment of an opioid overdose.
- Prohibits a plan contract or insurance policy imposing any cost-sharing requirements, including a copayment or deductible, for coverage. Requires a health plan or insurer to cover the total cost of prescription or nonprescription NH.
- Requires coverage of prescription or nonprescription NH under Medi-Cal, as specified.
- Makes Legislative findings and declarations including:
- In November 2022, the FDA issued a Federal Register notice with a preliminary assessment of the safety and effectiveness of certain NH drug products for nonprescription use, in order to facilitate the development and approval of those products, including through a potential switch from prescription status to nonprescription status;
- In February 2023, an advisory committee to the FDA voted unanimously in favor of making Narcan, a NH nasal spray, available over the counter (OTC); and,
- The FDA is expected to make a final decision by the end of March 2023 on whether to approve Narcan for nonprescription use.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975; the California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [Health and Safety Code (HSC) § 1340, et seq., Insurance Code (INS) §106, et seq., and Welfare and Institutions Code § 14000, et seq.]
- Establishes as California's essential health benefits (EHBs) benchmark under the Patient Protection and Affordable Care Act (ACA), the Kaiser Small Group Health Maintenance Organization, existing California health insurance mandates, and the 10 ACA mandated benefits, including prescription drug coverage. [HSC § 1367.005 and INS § 10112.27]
- Prohibits, with respect to an individual or group health plan contract or health insurance policy that covers EHBs, the copayment, coinsurance, or any other form of cost sharing for a covered outpatient prescription drug for an individual prescription for a supply of up to 30 days from exceeding $250; for a product with an actuarial value at or equivalent to a Bronze level, limits cost sharing to not more than $500 for a supply of up to 30 days; and for a high deductible health plan the $250 or $500 limits apply only after an enrollee’s deductible is met. [HSC § 1342.73 and INS § 10123.1932]
- Requires every health plan contract and insurance policy that provides hospital, medical, or surgical coverage to provide coverage for medically necessary treatment of mental health and substance use disorders (SUD) under the same terms and conditions applied to other medical conditions, as specified. [HSC § 1374.72 and INS § 10144.5]
- Requires the health plan or insurer, if services for the medically necessary treatment of a mental health or SUD are not available in network within the geographic and timely access standards set by law or regulation, to arrange coverage to ensure the delivery of medically necessary out-of-network services and any medically necessary follow-up services that, to the maximum extent possible, meet those geographic and timely access standards. This includes, but is not limited to, providing services to secure medically necessary out-of-network options that are available to the enrollee within geographic and timely access standards, and requires the enrollee or insured to pay no more than the same cost sharing that would be paid for the same covered services received from an in-network provider. [HSC § 1374.72 and INS § 10144.5]
- Classifies controlled substances under the California Uniform Controlled Substances Act (CUCSA), into five schedules and places the greatest restrictions and penalties on the use of those substances placed in Schedule I. Classifies the drug fentanyl in Schedule II. [HSC § 11054-11058]
- Authorizes the State Department of Public Health (DPH), in order to reduce the rate of fatal overdose from opioid drugs including heroin and prescription and illicit opioids, to award funding to local health departments, local government agencies, or on a competitive basis to community-based organizations, regional opioid prevention coalitions, or both, to support or establish programs that provide NH, or any other opioid antagonist that is approved by the FDA for the treatment of an opioid overdose, to first responders and to at-risk opioid users through programs that serve at-risk drug users, including, but not limited to, syringe exchange and disposal programs, homeless programs, and SUD treatment providers. [HSC § 1179.80]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, the danger of fentanyl to young kids is that it only takes two milligrams―smaller than a grain of rice―to end a life. NH saves lives by reversing opioid overdoses―but only if you can afford it. The author concludes that this bill will ensure that every parent, family member, or guardian can have access to this life-saving drug and protect their family members.
- BACKGROUND. According to the California Health Benefits Review Program (CHBRP) NH is an opioid antagonist, meaning that it binds to opioid receptors throughout the body, thus reversing and blocking the effects of opioids. NH can be used for all opioids, including natural compound opiates (such as morphine, heroin, and/or codeine), semi-synthetic opioids (such as hydrocodone, oxycodone, and/or hydromorphone), and synthetic opioids (such as fentanyl, carfentanil, and/or tramadol). NH is only effective for opioid overdose and has no effect on other common overdoses such as methamphetamines, benzodiazepines, or alcohol.
- Controlled Substances. Certain drugs are classified under the federal Controlled Substances Act of 1970 (CSA) into one of five schedules. Placement in a given schedule depends on whether a drug has a currently accepted medical use, its relative abuse potential, and its likelihood of causing either addiction or physical dependency when abused. Most opioid analgesics are Schedule II drugs, in that they have a recognized medical use, but also have a high potential for abuse that may lead to severe psychological and/or physical dependence. The CSA places a number of restrictions on prescribers and pharmacies that dispense controlled substances like opioids. For example, refills are not permitted and a new written prescription must be presented each time the drug is dispensed. Fentanyl is currently classified as Schedule II. CUCSA very closely mirrors the CSA related to drug/opioid classification.
- Fentanyl. Fentanyl is a potent synthetic opioid drug approved by the FDA for use as an analgesic and anesthetic. It is approximately 50 times stronger than heroin and 100 times stronger than morphine. First developed in 1959, it was introduced in the 1960’s as an intravenous anesthetic. Fentanyl is legally manufactured and distributed in the United States; however, there are two types of fentanyl: pharmaceutical fentanyl and illicitly manufactured fentanyl. Both are considered synthetic opioids. Pharmaceutical fentanyl is prescribed by doctors to treat severe pain, especially after surgery and for advanced-stage cancer. Most recently, cases of fentanyl-related overdoses are linked to illicitly manufactured fentanyl that is distributed through illegal drug markets for its heroin-like effect. It is often added to other drugs because of its extreme potency, which makes drugs cheaper, more powerful, more addictive, and more dangerous.
Fentanyl is a major contributor to fatal and nonfatal overdoses in California. In 2021, fentanyl was involved in over 83% of the 7,175 opioid related deaths. The number of deaths each year involving fentanyl increased dramatically between 2012 and 2021. During this time period fentanyl related overdose deaths increased by more than 7,250% from 82 to 5,961 in 2021.
The Centers for Disease Control and Prevention (CDC) reports that over 150 people die every day from overdoses related to synthetic opioids like fentanyl. According to the CDC, from 2016 to 2017 only three states, California, Illinois, and Virginia experienced a statistically significant change in overdose death rates involving synthetic opioids from 2016 to 2017. Eighteen states reflected no significant change in overdose deaths and 25 states plus the District of Columbia remained stable. In stark contrast, the 2019-2020 figures reflect that 40 states and the District of Columbia experienced a statistically significant increase in opioid related deaths while only four states did not have a significant increase and only seven states remained stable. - Reversing opioid overdoses. NH (Narcan) is an opioid antagonist that rapidly reverses an opioid overdose. It attaches to opioid receptors and reverses and blocks the effects of other opioids. NH can quickly restore normal breathing to a person if their breathing has slowed or stopped because of an opioid overdose. NH comes in two FDA-approved forms: injectable and prepackaged nasal spray.
Narcan nasal spray was first approved by the FDA in 2015 as a prescription drug. According to the FDA, in accordance with a process to change the status of a drug from prescription to nonprescription, the manufacturer provided data demonstrating that the drug is safe and effective for use as directed in its proposed labeling. The manufacturer also showed that consumers can understand how to use the drug safely and effectively without the supervision of a healthcare professional. The application to approve Narcan nasal spray for OTC use was granted priority review status and was the subject of an advisory committee meeting in February 2023, where committee members voted unanimously to recommend it be approved for marketing without a prescription.
On March 29, 2023 the FDA approved Narcan for nonprescription use. This is the first NH product approved for use without a prescription. This approval will allow this medication to be sold directly to consumers in drug stores, grocery stores, as well as online. According to an FDA Commissioner, “The approval of OTC NH nasal spray will help improve access to NH, increase the number of locations where it’s available and help reduce opioid overdose deaths throughout the country. We encourage the manufacturer to make accessibility to the product a priority by making it available as soon as possible and at an affordable price.” It is unknown when this product will become readily available for OTC purchase and what the cost will be.
- DPH statewide standing order for NH. NH can help reduce opioid overdose deaths but many organizations in California find it difficult to obtain the required standing order to obtain NH from health care providers. As such, DPH issued the standing order, in 2017, to address this need and support equitable NH access. The standing order:
- Allows community organizations and other entities in California that are not currently working with a physician, to distribute NH to a person at risk of an opioid-related overdose or to a family member, friend, or other person in a position to assist; and,
- Allows for the administration of NH by a family member, friend, or other person to a person experiencing or reasonably suspected of experiencing an opioid overdose.
- DPH statewide standing order for NH. NH can help reduce opioid overdose deaths but many organizations in California find it difficult to obtain the required standing order to obtain NH from health care providers. As such, DPH issued the standing order, in 2017, to address this need and support equitable NH access. The standing order:
Among the organizations and entities that can distribute NH under the order are colleges and universities. An individual at risk of experiencing an overdose or someone who can assist an individual at risk is allowed to do so. Under the statewide standing order, staff of community organizations and other entities distributing NH must be trained. They are also required to provide training to individuals who receive NH from them. Colleges and other organizations may apply to use the statewide standing order if they meet certain conditions.
- NH Distribution Program (NDP). Established in October of 2018, the NDP aims to reduce opioid overdose deaths through the provision of free NH in nasal spray and intramuscular formulations. The NDP is funded by State General Funds, Opioid Settlement Funds, and federal grants and is administered by DHCS. Entities apply to DHCS to have NH shipped directly to their address. Eligible entities under the NDP include law enforcement agencies such as police departments, county jails and probation departments; fire, emergency medical services, and first responders; schools and universities, county public health and behavioral health departments; tribal agencies, harm reduction organizations; and, community organizations such as local opioid coalitions.
As of March 6, 2023, the NDP had approved more than 7,200 applications; distributed more than 2.1 million NH kits; and had reported opioid overdose reversals of more than 137,000.
The NDP application process requires applicants to agree to the following terms and conditions:- Certify that the authorized person, communication, and mailing information is correct;
- Ensure that any of its affiliates or subcontractors apply for their organization;
- Agrees to provide a copy of a valid and active business license, Federal Employer ID Number or tax exempt letter;
- Agree to provide a copy of a NH standing order that can be obtained at DPH standing order application or a physician’s prescription;
- If the NH request is for more than 48 units, the organization/entity will provide a comprehensive summary with the application to validate their request;
- Agree to allow the DHCS to contact the organization/entity using the information provided on the application form; and,
- Agree to allow the DHCS to use the information provided on the application form to track the use of the NH distribution and conduct other public health and epidemiological surveillance activities.
- CHBRP analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP reviewed AB 1060 and states the following in its analysis:
- Enrollees covered. This bill would apply to the health insurance of 24,853,000 California enrollees (64% of all Californians). This represents those who have commercial or CalPERS health insurance regulated by DMHC and CDI and Medi-Cal beneficiaries enrolled in DMHC-regulated plans or county organized health systems.
- Impact on expenditures. Postmandate, 100% of the 24,982,000 enrollees will have coverage fully compliant with this bill, meaning prescription and nonprescription NH would be covered without cost sharing. Since there are no estimates available as to the utilization rate of nonprescription NH, as an illustrative example, CHBRP assumed 20% of enrollees with an opioid addiction would receive one kit of nonprescription NH postmandate and 5% of commercial and Medi-Cal enrollees with an opioid addiction would have one family member who would also receive one kit of nonprescription NH. CHBRP estimates that prescription NH (nasal sprays and injections) prescriptions will increase by 1,410 from 38,850 to 40,260, a 3.63% increase. Nonprescription NH (nasal sprays) covered by insurers will increase from 0 to 77,580. The increased utilization is driven both by the proposed legislation’s removal of cost sharing as well as by removal of the need for a prescription. Since Medi-Cal plans do not have cost sharing, the prescription utilization rate for Medi-Cal enrollees remains unchanged postmandate. State expenditures for Medi-Cal would increase by $1,328,000, or 0.003%. This bill would increase total net annual expenditures by $9,218,000 or 0.006% for enrollees with DMHC-regulated plans and CDI-regulated policies.
- EHBs. Since prescription drugs are an EHB category, the portion of this bill that requires coverage of prescription NH does not exceed the definition of EHBs in California. It is unclear whether the requirement to provide coverage of nonprescription NH without cost sharing would exceed EHBs. Although medically necessary treatment for SUD within applicable clinical guidelines is within the EHB standard, as is emergency care, the circumstances under which nonprescription NH may be obtained may not fall within these categories.
- Public health. CHBRP estimates this bill would result in increased distribution of NH, which would contribute to increased treatment of opioid overdoses and a potential reduction in mortality. This estimate is supported by evidence that use of NH is medically effective in reversing opioid overdose and an increase in distribution of NH. However, CHBRP is unable to quantify the extent to which reductions in mortality would occur due to uncertainties about the degree to which distribution of NH would occur postmandate. According to CHBRP, this bill would contribute to a decrease in fatalities from opioid overdose, although the extent to which this would occur is unknown.
- Long-term impacts. The long-term impact depends on the extent to which reductions in cost sharing and prescription requirements will lead to increased access and whether that increased access will lead to increased use of NH to treat opioid use overdose. People whose lives are saved with NH treatment may have different cost trajectories that those modeled in the short term. After an overdose, an enrollee may be seen by emergency medical personnel, seen in an emergency department, or seek treatment for an opioid use disorder. All of these actions would result in additional health expenditures over time.
- NH Distribution Program (NDP). Established in October of 2018, the NDP aims to reduce opioid overdose deaths through the provision of free NH in nasal spray and intramuscular formulations. The NDP is funded by State General Funds, Opioid Settlement Funds, and federal grants and is administered by DHCS. Entities apply to DHCS to have NH shipped directly to their address. Eligible entities under the NDP include law enforcement agencies such as police departments, county jails and probation departments; fire, emergency medical services, and first responders; schools and universities, county public health and behavioral health departments; tribal agencies, harm reduction organizations; and, community organizations such as local opioid coalitions.
- SUPPORT. California’s Attorney General writes that having NH more widely available is an important piece to addressing the opioid crisis. In California, there were 7,175 deaths related to an opioid overdose in 2021, and 5,961 of those deaths were specifically attributed to Fentanyl. Fentanyl is a powerful and potentially addictive synthetic opioid that is up to 50 times stronger than heroin. A small amount of fentanyl, just two milligrams, can result in overdose and potentially death. This opioid crisis is a multifaceted public health and safety issue. Addressing this crisis requires a thoughtful and strategic approach. The California Department of Justice (DOJ) works with local and federal law enforcement partners through the Fentanyl Enforcement Program to detect, deter, disrupt, and dismantle criminal fentanyl operations. DOJ’s ongoing work to address the fentanyl crisis includes the seizure of over four million fentanyl pills and almost 900 pounds of fentanyl powder, and over 200 arrests through the DOJ’s Bureau of Investigation and work with allied task forces throughout California since April 2021.
- OPPOSITION. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All ACA-compliant plans provide a robust package of EHBs in the large group, small business, and individual markets. In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates. The opposition states all of these bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options.
- RELATED LEGISLATION.
- AB 1288 (Reyes) prohibits a medical service plan and a health insurer from subjecting a buprenorphine product, methadone, or long-acting injectable naltrexone for detoxification or maintenance treatment of a SUD that is prescribed according to generally accepted national professional guidelines for the treatment of a SUD to prior authorization. AB 1288 is pending in Assembly Health Committee.
- AB 24 (Haney) requires a person or entity that owns, manages, or is responsible for a designated facility, defined as a bar (as defined) gas station, public library, residential hotel (as defined) in a county that is experiencing an opioid overdose crisis, as defined by DPH, to acquire and post an opioid antagonist kit, which includes an instructional poster and opioid antagonist nasal spray, in areas that are readily accessible only by employees, including, but not limited to, a break room, and to restock the opioid antagonist kit after each use. Provides immunity for liability. Requires DPH to identify the at risk counties, provide opioid antagonist kits free of charge, create the opioid antagonist poster with easy-to-understand instructions and graphics on the administration of the attached opioid antagonist nasal spray, and to make the determination on how best to allocate and distribute its limited supply of opioid antagonist among its various programs in the event of an opioid antagonist supply shortage. Makes a violation of these subject to a civil penalty of not more than $100. AB 24 is pending in the Assembly Judiciary Committee.
- AB 1233 (Waldron) requires DHCS to conduct an outreach program to each of the tribal governments in California for the purpose of advising them of the availability of NH or another opioid antagonist through the DHCS’ NDP. Requires DHCS to also provide technical assistance, if requested by the tribal government, to those tribal entities applying for NH kits through the NDP. Requires, beginning March 31, 2025, DHCS to report annually specified data to the Legislature and to the Assembly and Senate Health Committees on the results of the outreach program on or before March 31 of each year. AB 1233 is pending in Assembly Appropriations Committee.
- POLICY COMMENTS.
- This bill requires coverage for nonprescription NH. According to CHBRP, there are some uncertainties regarding how nonprescription NH will be available. While nonprescription NH is able to be sold “over the counter,” pharmacies or stores may decide to keep NH behind the pharmacist counter or behind protected glass, thereby requiring a shopper to ask for access to NH. Additionally, since this bill would require insurance coverage without cost sharing for NH, it is unclear how this provision will be implemented. CHBRP states that enrollees whose health insurance would be subject to this bill may, for example, file for reimbursement from their insurer after paying out of pocket for NH at the time of purchase or may purchase NH through a pharmacy that is able to directly bill their insurance company.
- Covered California, California’s health benefit exchange, annually considers standard benefit designs that meet actuarial value requirements established by the ACA. As this bill moves forward, the author may wish to consider a delayed implementation for health plan coverage to address changes to Covered California’s standard benefit design, if any.
- EHBs. It is unclear whether the requirement to provide coverage of nonprescription NH without cost sharing would exceed EHBs and if the state has to defray the costs. At this time, it is unknown whether the relevant state regulators have analyzed this bill’s impact on EHBs.
REGISTERED SUPPORT / OPPOSITION:
Support
Attorney General Rob Bonta
California Nurses Association
California Professional Firefighters
California Society of Addiction Medicine
County Behavioral Health Directors Association of California
County Health Executives Association of California (CHEAC)
Eden Health District
Eden Youth and Family Center
Horizon Services, INC.
LA Clinica de LA Raza, INC.
Latino Coalition for A Healthy California
National Health Law Program
Western Center on Law & Poverty, INC.
Opposition
America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):